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ABSTRACT 
Mutations in TSC2 cause the disorder tuberous sclerosis (TSC), which has a high 
incidence of autism and intellectual disability. TSC2 regulates mRNA translation 
required for group 1 metabotropic glutamate receptor-dependent synaptic long-term 
depression (mGluR-LTD), but the identity of mRNAs responsive to mGluR-LTD 
signaling in the normal and TSC brain is largely unknown. We generated Tsc2+/- mice to 
model TSC autism and performed ribosome profiling to identify differentially expressed 
genes following mGluR-LTD in the normal and Tsc2+/- hippocampus. Ribosome profiling 
reveals that in Tsc2+/- mice, RNA-binding targets of Fragile X Mental Retardation Protein 
(FMRP) are increased. In wild-type hippocampus, induction of mGluR-LTD caused rapid 
changes in the steady state levels of hundreds of mRNAs, many of which are FMRP 
targets. Moreover, mGluR-LTD signaling failed to promote phosphorylation of 
eukaryotic elongation factor 2 (eEF2) in Tsc2+/- mice, and chemically mimicking 
phospho-eEF2 with low cycloheximide enhances mGluR-LTD in the Tsc2+/- brain. These 
results suggest a molecular basis for bidirectional regulation of synaptic plasticity by 
TSC2 and FMRP. Furthermore, deficient mGluR-regulated translation elongation 
contributes to impaired synaptic plasticity in Tsc2+/- mice. 
  
	
 
vi	
vi 
TABLE OF CONTENTS 
Reviewer page .................................................................................................................... ii	
Acknowledgements ........................................................................................................... iii	
Abstract .............................................................................................................................. v	
Table of Contents ............................................................................................................. vi	
List of Figures ................................................................................................................... ix	
List of Tables ..................................................................................................................... xi	
Glossary of Terms  .......................................................................................................... xii	
 
Chapter I Introduction ..................................................................................................... 1	
 
Overview of tuberous sclerosis .................................................................................................. 1	
Clinical features of tuberous sclerosis ..................................................................................... 1	
Genetics of tuberous sclerosis ................................................................................................. 2	
TSC is an inhibitor of mTOR signaling ................................................................................... 3	
Neurological functions of TSC ................................................................................................ 5	
Treatment options for TSC ...................................................................................................... 6	
Overview of Fragile X Syndrome ............................................................................................. 7	
Genetics of Fragile X Syndrome ............................................................................................. 7	
Clinical features of Fragile X Syndrome ................................................................................. 8	
Molecular function of FMRP ................................................................................................... 8	
Treatment options for FXS ...................................................................................................... 9	
Protein homeostasis in synaptic plasticity ............................................................................... 9	
Optimal neural performance depends on protein homeostasis ................................................ 9	
Some forms of memory require rapid protein synthesis ........................................................ 10	
Synaptic plasticity depends on local, activity-dependent translation in neurons .................. 12	
Translational regulation in synaptic plasticity ...................................................................... 13	
	
 
vii	
vii 
Regulators of translation initiation in synaptic plasticity ...................................................... 13	
Regulation of translation elongation in synaptic plasticity .................................................... 21	
Convergence of mGluR5 and mTOR signaling on ASD ....................................................... 23	
Chapter II Ribosome Profiling in Mouse Hippocampus: Plasticity-induced 
Regulation and Bidirectional Control by TSC2 and FMRP ....................................... 27	
 
Preface ....................................................................................................................................... 28	
Introduction .............................................................................................................................. 28	
Results ....................................................................................................................................... 32	
Translational Profiling of the TSC hippocampus .................................................................. 32	
Dysregulation of 5′ terminal oligopyrimidine (TOP) mRNAs in Tsc2+/- ........................... 37	
FMRP binding targets are altered in opposite directions in TSC and FXS mice .................. 43	
mGluR5 signaling induces a rapid RNA and translational response ..................................... 46	
mGluR-induced translational dysregulation in TSC .............................................................. 51	
Signaling to eukaryotic elongation factor 2 is altered in the Tsc2+/- hippocampus ............... 53	
Discussion .................................................................................................................................. 59	
Limitations ................................................................................................................................ 67	
Conclusions ............................................................................................................................... 67	
Materials and methods ............................................................................................................ 67	
Acknowledgements ................................................................................................................... 77	
Chapter III Global Profiling of Translation by FMRP-associated Ribosomes ......... 78	
 
Preface ....................................................................................................................................... 79	
Introduction .............................................................................................................................. 79	
Results ....................................................................................................................................... 84	
FMRP interacts with ribosomal proteins after RNase digestion ........................................... 84	
	
 
viii	
viii 
Anti-FMRP enriches for specific RPFs over total ribosomes ............................................... 88	
Anti-FMRP enriches for specific RPFs independent of FMRP ............................................. 93	
SeRP in FMRP-FLAG neural progenitor cells ...................................................................... 97	
Technical challenges to overcome for FMRP SeRP .............................................................. 99	
Discussion ................................................................................................................................ 102	
Overlapping function of FXRs and FMRP .......................................................................... 102	
Auto-regulation of Fmr1 translation by FMRP ................................................................... 103	
FMRP-ribosome interaction ................................................................................................ 104	
Materials and methods .......................................................................................................... 107	
Acknowledgements ................................................................................................................. 112	
Chapter IV Discussion and Conclusions ..................................................................... 121	
 
Summary ................................................................................................................................. 121	
FMRP binding targets connects mGluR-LTD with two mouse models of autism ........... 122	
TSC2: potential regulator of mGluR-LTD signaling to eEF2 and FMRP ....................... 123	
Altered eEF2K/eEF2 signaling may underlie other phenotypes in Tsc2+/- mice .............. 124	
Crosstalk of eEF2K/eEF2 signaling and TOP mRNAs in Tsc2+/- animals ........................ 125	
Role of mRNA turnover and stability in mGluR-LTD ....................................................... 126	
Limitations of mouse models of TSC and whole tissue sequencing ................................... 129	
Concluding remarks .............................................................................................................. 131	
REFERENCES .............................................................................................................. 132	
 
  
	
 
ix	
ix 
LIST OF FIGURES 
Figure I.1: Overview of TSC/mTOR signaling ................................................................... 5	
Figure I.2: Connection between synaptic plasticity and activity-dependent local 
translation in the hippocampus .................................................................................. 11	
Figure I.3: Major steps of cap-dependent translation initiation ........................................ 15	
Figure I.4: Overview of translation signaling pathways important for mGluR-LTD ....... 20	
Figure I.5: mGluR5 and mTORC1 signaling to translation .............................................. 26	
Figure II.1: Schematic of experimental design ................................................................. 33	
Figure II.2: Ribosome profiling of Tsc2+/- hippocampal slices reveals RNA and RPF 
dysregulation ............................................................................................................. 36	
Figure II.3: Dysregulation of TOP mRNAs in Tsc2+/- ...................................................... 38	
Figure II.4: Lack of unique 5′UTR features in dysregulated RPFs from Tsc2+/- ........... 39	
Figure II.5: Correlation of hippocampal TE with degree of dysregulation in Tsc2+/- ....... 41	
Figure II.6: Transcript features of hippocampal TE .......................................................... 42	
Figure II.7: FMRP binding targets are regulated by TSC2 and FMRP in opposing 
directions ................................................................................................................... 45	
Figure II.8: mGluR signaling induces rapid RNA and RPF changes in wild-type 
hippocampal slices .................................................................................................... 48	
Figure II.9: Gene set enrichment analysis of mGluR-responsive RNAs .......................... 49	
Figure II.10: Gene set enrichment analysis of mGluR-responsive RPFs .......................... 50	
Figure II.11: Some mRNAs altered in unstimulated Tsc2+/- slices do not respond to 
DHPG-mGluR signaling ........................................................................................... 52	
	
 
x	
x 
Figure II.12: Deficient mGluR1/5-regulated signaling to translation elongation in Tsc2+/- 
mice ........................................................................................................................... 54	
Figure II.13: Correlation of hippocampal TE with mGluR5-responsive mRNAs and 
FMRP binding targets ............................................................................................... 56	
Figure II.14: Low dose cycloheximide enhances LTD in Tsc2+/- ..................................... 58	
Figure II.15: Model of altered eEF2 signaling and FMRP binding targets in Tsc2+/- ...... 66	
Figure III.1: Comparison of conventional and selective ribosome profiling .................... 83	
Figure III.2: FMRP co-sediments with ribosomal proteins independent of RNA ............ 85	
Figure III.3: FMRP interacts with ribosomal proteins independent of RNA .................... 87	
Figure III.4: Gene body mapping frequency for conventional and selective ribosome 
profiling ..................................................................................................................... 89	
Figure III.5: Anti-FMRP enriches for specific mRNAs .................................................... 90	
Figure III.6:  Different modes of binding by anti-FMRP ribosomes ................................ 92	
Figure III.7: Anti-FMRP enriches for specific mRNAs independent of FMRP ............... 94	
Figure III.8: Anti-FMRP cross-reacts to paralogue FXR2P ............................................. 96	
Figure III.9: FMRP-FLAG cosediments with polysomes similar to wild-type FMRP ..... 98	
Figure III.10: Crosslinking stabilizes some FMRP-ribosome interaction ....................... 101	
 
  
	
 
xi	
xi 
LIST OF TABLES 
Table III-1: List of sample types and purpose for FMRP selective ribosome profiling ... 88	
Table III-2: List of 125 mRNAs enriched in anti-FMRP ribosomes .............................. 113	
 
  
	
 
xii	
xii 
GLOSSARY OF TERMS  
 Full name Definition 
CHX cycloheximide A translation elongation inhibitor that is used to immobilize ribosomes on mRNAs.  
CLIP Cross linking immunoprecipitation 
A method that combines UV light cross-linking and 
immunoprecipitation to identify mRNA targets of 
RNA-binding proteins.  
DE  differentially expressed 
A statistically significant difference in expression 
levels between two experimental groups or 
conditions (knockout versus wild-type, treated versus 
untreated). 
DHPG  dihydroxyphenylglycine 
A selective and potent agonist for group 1 
metabotropic glutamate receptors 1 and 5 
(mGluR1/5). Treatment with DHPG induces long-
term depression in the hippocampus.  
eEF2 eukaryotic elongation factor 2 
A member of the GTP-binding elongation factor 
family that mediates translocation of the peptidyl-
tRNA from the A site to the P site of the ribosome. 
eEF2K eukaryotic elongation factor 2 kinase 
A kinase that phosphorylates its sole substrate eEF2 
on Thr56 to inactivate the function of eEF2.   
FMRP Fragile X Related Protein 
An RNA-binding protein whose loss causes Fragile 
X Syndrome. FMRP binds mRNAs to control their 
transport, stability, and translation required for 
neuron-to-neuron communication.  
FXR Fragile X Related proteins 
A family of RNA-binding proteins that include 
FMRP and its paralogs FXR1P and FXR2P.  
FXS Fragile X Syndrome 
The leading single-gene cause of intellectual 
disability and autism spectrum disorder that arises 
from the absence of FMRP.   
LTD  long-term depression  
A form of synaptic plasticity characterized by a 
persistent activity-dependent decrease in synaptic 
transmission that lasts greater than 1 hour.  
LTP long-term potentiation 
A form of synaptic plasticity characterized by a 
persistent activity-dependent increase in synaptic 
transmission that lasts greater than 1 hour. 
mGluR-
LTD 
metabotropic group 1 
mediated long-term 
depression 
A form of LTD that depends on rapid protein 
synthesis following activation of mGluR5 signaling 
by DHPG. mGluR-LTD in this document refers 
specifically to mGluR5-LTD in the CA1 region of 
the hippocampus. 
mGluR5 metabotropic glutamate receptor 5 
A G-protein-coupled receptor that is a member of the 
group 1 metabotropic glutamate receptors. Activation 
of mGluR5 by the agonist DHPG leads to LTD in the 
hippocampus.  
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mTORC1 mechanistic target of rapamycin complex 1 
A multi-subunit serine/threonine kinase complex that 
is a master regulator of cellular homeostasis and 
protein synthesis.  
RBP RNA-binding protein A protein that binds RNA to regulate its processing, localization, turnover, and translation 
RPF ribosome protected fragment 
A ~30nt portion of mRNA that is protected by the 
ribosome after RNase digestion. RPFs reveal the 
location and density of ribosomes on mRNA.  
SeRP Selective ribosome profiling 
A method to perform ribosome profiling on a specific 
ribosome population, usually by enrichment from 
affinity purification.  
TE translation efficiency A ratio of RPF to RNA levels commonly used in ribosome profiling experiments.    
TOP terminal oligopyrimidine tract 
A stretch of pyrimidines immediately after the 5′cap 
of mRNAs. Present in many mRNAs that encode 
components of the translation machinery and 
translation factors.  
TSC tuberous sclerosis complex 
An autosomal dominant disorder caused by loss of 
function mutations in TSC1 or TSC2. TSC can also 
refer to the protein complex made up of TSC1 and 
TSC2, which is a potent inhibitor of mTOR 
signaling.  
TSC1 tuberous sclerosis complex 1 
The protein product of TSC1, also known as 
hamartin. TSC1 interacts with TSC2 to stabilize the 
complex TSC.  
TSC2 tuberous sclerosis complex 2 
The protein product of TSC2, also known as tuberin, 
which encodes a GTPase-activating protein. TSC2 
interacts with TSC1 to form the complex TSC. 
UTR untranslated region 
The regions upstream (5′) or downstream (3′) of the 
main coding sequence of an mRNA. Often contains 
regulatory sequences for RBPs to bind.  
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CHAPTER I INTRODUCTION 
Overview of tuberous sclerosis  
Clinical features of tuberous sclerosis  
Tuberous sclerosis (TSC) is a multi-organ disorder characterized by hamartomas, 
benign tumors that contain multiple cell types. Hamartomas in TSC are frequently 
observed in the skin, kidneys, lungs, heart, eyes, and brain. Because TSC1 and TSC2 
encode tumor suppressors, individuals with TSC also have a higher risk of invasive 
malignancy. Roughly 80% of patients have hamartomatous lesions in the brain, referred 
to as cortical tubers. Cortical tubers form during early development and contain a mixture 
of undifferentiated, abnormal neurons and glia. Cortical tubers are generally benign and 
do not increase in size or number. Subependymal giant cell tumors (SEGA) are also 
commonly found in patients with TSC (~10%). SEGAs contain glial cells, and unlike 
cortical tubers, can slowly grow in size and number. In addition to the anatomical 
abnormalities, individuals with TSC also have a high incidence of neuropsychiatric 
symptoms that collectively form the tuberous sclerosis associated neuropsychiatric 
disorder (TAND) (Krueger and Northrup 2013). Individuals with TSC have a high 
incidence of epilepsy (90%), intellectual disability/cognitive deficits (~50%), autism 
(~40%), and other behavioral problems such as aggression and attention deficit disorder. 
The neurological symptoms have the largest burden on quality of life for individuals with 
TSC and their caregivers (Hallett, Foster et al. 2011). Because the majority of patients 
with TSC have brain lesions, scientists and physicians initially proposed that the lesions 
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were the main driver for the neuropsychiatric symptoms. However, lesion burden is only 
mildly correlated with the severity of neurological complications. For example, seizures 
in TSC can originate outside of cortical hamartomatous legions. Furthermore, some 
patients with an anatomically normal brain can have severe cognitive dysfunction and 
conversely, patients with a high lesion load can have minimal cognitive impairment 
(Smalley, Burger et al. 1994, Ridler, Suckling et al. 2004, Wong and Khong 2006). 
Genetics of tuberous sclerosis  
TSC is an autosomal dominant disorder with an incidence of 1 in 6,000-10,000. 
Roughly two-thirds of cases are caused by de novo mutations, and the remaining cases 
are familial (Northrup, Kwiatkowski et al. 1992, Sampson and Harris 1994). TSC is 
caused by loss of function of either tumor suppressor gene TSC1 or TSC2. Thousands of 
variants have been reported for TSC1/2 and include a wide spectrum of small deletions, 
insertions, missense, nonsense, and splicing site mutations (Rosset, Netto et al. 2017). 
Most cases of TSC are sporadic; mutations in TSC2 are more common and associated 
with a more severe clinical presentation than mutations in TSC1 (Au, Williams et al. 
2007). TSC is also a highly heterogeneous disorder with variable penetrance and 
expressivity. Some individuals with TSC remain undiagnosed for years, while others can 
have severe neurocognitive impairments requiring social services. Variable expressivity 
in TSC arises even within the same family, highlighting the role of other environmental 
and genetic modifiers (Smalley, Burger et al. 1994). Thus, genotype-phenotype 
correlations for TSC are challenging due to the thousands of reported mutations and 
variable expressivity. 
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TSC is an inhibitor of mTOR signaling  
TSC1 and TSC2 encode hamartin and tuberin respectively, which together form 
the protein complex tuberous sclerosis complex (TSC) (van Slegtenhorst, de Hoogt et al. 
1997). TSC2/tuberin is a GTPase activating protein that inactivates the GTP-binding 
protein Ras homology enriched in brain (Rheb) (Sampson and Harris 1994, Inoki, Li et 
al. 2002). In response to upstream signaling from insulin, amino acids, oxygen levels, and 
growth factors that converge on AKT and ERK, TSC is inactivated by phosphorylation of 
TSC2. Following inactivation of TSC, Rheb activates the mechanistic target of 
rapamycin complex 1 (mTORC1), a multi-unit serine/threonine kinase that is a master 
regulator of cell proliferation and growth (Inoki, Li et al. 2002, Inoki, Li et al. 2003, 
Yang, Inoki et al. 2006). mTORC1 phosphorylates hundreds of downstream substrates to 
increase anabolic and decrease catabolic processes (Figure I.1). 
mTORC1 broadly regulates cell homeostasis and growth through increasing 
translation, increasing specific gene expression programs, and inhibiting protein turnover. 
Translational control is the best-studied mTORC1-dependent process. mTORC1 
signaling broadly increases protein synthesis capacity of cells by directly activating 
translation factors and regulators. In addition, mTORC1 signaling increases translation of 
mRNAs encoding the translation machinery and translation factors to further support 
increased protein synthesis. In parallel with the translational response, mTORC1 can 
activate the following transcription factors to support anabolic processes: lipogenesis via 
SREBP (Düvel, Yecies et al. 2010), glycolysis via HIF1a (Hudson, Liu et al. 2002, 
Düvel, Yecies et al. 2010), and mitochondria biogenesis via PGC1a. mTORC1 also 
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directly reduces protein turnover by inhibiting autophagy, lysosome biogenesis, and 
proteasome assembly (Peña-Llopis, Vega-Rubin-de-Celis et al. 2011, Settembre, Zoncu 
et al. 2012, Di Nardo, Wertz et al. 2014).  
TSC-Rheb-mTORC1 is the canonical signaling pathway, but TSC can regulate 
non-mTORC1 processes (Neuman and Henske 2011). TSC controls cytoskeletal 
dynamics and cell adhesion by directly binding to the ezrin-radixin-moesin family of 
actin-binding proteins and activating the small GTPase Rho (Lamb, Roy et al. 2000, 
Astrinidis, Cash et al. 2002). Rheb can also activate processes independent of mTORC1. 
Overexpression of inactivated Rheb rescues dendritic spine morphogenesis in TSC-
deficient neurons, but not mTORC1 knockdown or rapamycin treatment, suggesting that 
this phenotype is mediated by Rheb hyperactivation independent from mTORC1 
signaling. Finally, there is also cross talk between mTORC1 and mTORC2, a structurally 
and functionally distinct mTOR complex with roles in cytoskeletal rearrangement. TSC is 
required for proper mTORC2 function through AKT signaling (Huang and Manning 
2009). 
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Figure I.1: Overview of TSC/mTOR signaling 
mTOR integrates signaling from multiple membrane receptors to maintain 
cellular homeostasis. The best characterized mTOR-dependent processes 
are depicted. TrkB: tyrosine receptor kinase B, NMDA-R: N-methyl-D-
aspartate receptor, mGluR5: metabotropic glutamate receptor 5. Accessory 
proteins for mTORC1 and mTORC2 are excluded for simplicity. Colors 
indicate positive regulators (green) and negative regulators (red) of mTOR 
signaling. 
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Neurological functions of TSC 
TSC/mTOR signaling has a role in maintenance of neural stem cells, neurite 
growth, and synaptic plasticity. Proper mTOR signaling is required for neural stem cell 
proliferation and differentiation. TSC2-deficient neural stem cells exhibit increased 
proliferation and favor glial over neuronal differentiation, which may contribute to the 
development of cortical tubers during embryogenesis (Grabole, Zhang et al. 2016). TSC 
is also required for proper dendritic and axonal growth. In Tsc1 haploinsufficient mice, 
neurons have increased soma size and decreased spine density (Tavazoie, Alvarez et al. 
2005). Tsc2-deficient neurons have increased number of axons via increased activity of 
SAD kinase, an important regulator of neuron polarity and axonogenesis (Choi, Di Nardo 
et al. 2008). TSC2 also regulates axon guidance in the visual system in an ephrin-Eph 
dependent manner (Nie, Di Nardo et al. 2010).  
 
Treatment options for TSC 
 Because excessive mTORC1 signaling underlies many pathogenic mechanisms 
arising from TSC haploinsufficiency, chemical inhibitors of mTOR are the main TSC-
specific therapeutic (Hallett, Foster et al. 2011, Sadowski, Kotulska et al. 2016). 
Everolimus is FDA-approved for treatment of several TSC-specific pathologies. 
Everolimus has been shown to decrease tumor size in SEGA and is used in patients who 
are non-surgical candidates (Krueger, Care et al. 2010). Roughly two-thirds of patients 
with TSC have seizures refractory to standard anti-epileptic drugs. In these cases, 
everolimus is effective in treating the refractory seizures by reducing frequency in 90% 
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and completely eliminating seizures in 33% of subjects (French, Lawson et al. 2016). For 
the neuropsychiatric symptoms of TSC, there currently are no TSC-specific treatments. 
Several randomized control clinical trials found that everolimus did not improve 
neurocognition, intellectual disability, or autism in children with TSC (Krueger, 
Sadhwani et al. 2017, Overwater, Rietman et al. 2019). This was a disappointing result in 
the field, despite evidence in mouse models of TSC that demonstrated improvement in 
various behavioral assays with rapamycin. Thus, the therapeutic options for the treatment 
of neuropsychiatric symptoms of TSC remain limited (Hallett, Foster et al. 2011). A 
remaining question is if other rapamycin-insensitive processes contributes to ASD-like 
behaviors in humans and mouse models. 
Overview of Fragile X Syndrome 
Genetics of Fragile X Syndrome 
Fragile X Syndrome (FXS) is the leading single-gene cause of intellectual 
disability and roughly one-third of individuals also have autism spectrum disorder (ASD).  
Initial karyotypes of FXS patients showed a piece missing from the X chromosome, from 
which the disorder is named (Oberlé, Rousseau et al. 1991). FXS is an X-linked disorder 
caused by a CGG repeat expansion in the 5′ untranslated region (5′UTR) of the Fragile X 
Mental Retardation 1 gene (FMR1) (Verkerk, Pieretti et al. 1991). Normal individuals 
have <50 CGG repeats and permutation carriers have 50 to 200 repeats. With over 200 
repeats, FMR1 is methylated and expression of the protein product Fragile X Mental 
Retardation Protein (FMRP) is reduced or absent, leading to the disorder (Pieretti, Zhang 
et al. 1991). The incidence of FXS ranges from 1 in 4,000-7,000 in males. Females can 
	
 
8	
8 
also be affected, though usually in a milder manner. Although premutation carriers do not 
develop FXS, they can present with Fragile X-associated tremor/ataxia, a late onset 
neurodegenerative disorder with neurocognitive impairment (Bagni, Tassone et al. 2012). 
Clinical features of Fragile X Syndrome 
The main symptoms of FXS are developmental delays, learning disabilities, and 
behavioral problems. Many individuals have intellectual disability and language delays, 
which can range from mild to severe. Over half of males with FXS have ASD, and FXS 
is one of the leading genetic syndromes associated with ASD (Richards, Jones et al. 
2015). Other common features include sensory disorders, anxiety, attention deficit 
disorder, aggression, and seizures (Bagni, Tassone et al. 2012). Physical characteristics of 
males with FXS include an elongated face, large ears, a prominent jaw, and 
macroorchidism. Infants with FXS can have macrocephaly, but otherwise display no 
brain structural abnormalities. 
Molecular function of FMRP 
FMR1 encodes Fragile X Mental Retardation Protein (FMRP), an RNA binding 
protein required for normal brain development and synaptic function. In mice, FMRP 
binds roughly 5% of brain mRNAs to regulate mRNA transport, stability, and 
translational repression of its targets. (Darnell, Van Driesche et al. 2011, Maurin, 
Lebrigand et al. 2018, Sawicka, Hale et al. 2019). Targets of FMRP overlap with genes 
linked to ASD and synaptic structure and function, and an important role of FMRP is to 
tightly control the synaptic proteome in response to neuronal activity (Huber, Gallagher 
et al. 2002, Bagni and Zukin 2019).  
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Treatment options for FXS  
There currently is no FXS-specific treatment or cure. For FXS and other 
developmental disorders such as TSC and ASD, a treatment plan involves a multi-
disciplinary approach with early intervention services and medication to address 
behavioral problems. FDA-approved drugs for the management of behavioral problems 
in FXS and ASD are anti-psychotics for aggression and stimulants for attention deficit 
disorders. Based on promising preclinical results in mice, metabotropic glutamate 
receptor 5 (mGluR5) inhibitors were developed to treat FXS (Bear, Huber et al. 2004, 
Dölen, Osterweil et al. 2007). However, randomized control studies using the mGluR5 
inhibitor mavoglurant did not improve behavioral symptoms in adolescents and adults 
with FXS (Berry-Kravis, Des Portes et al. 2016). Because a criticism of these clinical 
trials included the use of subjects who are past the optimal window of brain plasticity, 
mGluR5 inhibitors are still being evaluated as a therapeutic option for FXS.  
Protein homeostasis in synaptic plasticity  
Optimal neural performance depends on protein homeostasis  
Certain brain regions exhibit high levels of plasticity during neurodevelopment, 
where neural circuits have a heighted sensitivity to inputs. Because ASD is a 
neurodevelopmental disorder, disruptions during this critical period of plasticity have a 
large and lasting impact on neural circuit maturation. Kelleher and Bear proposed that 
optimal neuronal performance depends on tightly regulated synaptic protein synthesis, 
and when synaptic protein homeostasis is disrupted, the subsequently altered neural 
circuitry can contribute to ASD (Kelleher and Bear 2008).  Support for their model 
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comes from the observation that 1) multiple genetic syndromes that have a high 
prevalence of ASD encode for translation repressors (e.g. FMRP in Fragile X Syndrome, 
TSC1/2 in TSC-associated neuropsychiatric disorder, and PTEN-associated autism), 2) 
multiple mouse models of ASD have altered global protein synthesis in the brain, and 3) 
restoring protein homeostasis in some mouse models of ASD can rescue molecular, 
synaptic, and behavioral phenotypes associated with autism (Auerbach, Osterweil et al. 
2011, Bhattacharya, Kaphzan et al. 2012, Udagawa, Farny et al. 2013).  
Some forms of memory require rapid protein synthesis 
Rapid protein synthesis in the hippocampus is required for some forms of long-
term memories (Hernandez and Abel 2008). Flexner et al first demonstrated that 
application of puromycin (a premature nascent chain terminator of protein synthesis) 
prevents mice from learning a discriminative avoidance task in mice (Flexner, Flexner et 
al. 1962, Flexner, Flexner et al. 1963). Thus, how is the requirement for protein synthesis 
in some forms of learning and memory translated on a molecular level? Synaptic 
plasticity is the ability of synapses to change persistently following a stimulus and is 
believed to underlie learning and memory. There are two forms of synaptic plasticity: 
long-term potentiation (LTP) and long-term depression (LTD). LTP is a persistent 
strengthening of a synaptic connection whereas LTD is a persistent weakening. Synaptic 
plasticity is best studied at the Schaffer collateral synapses in the CA1 region of 
hippocampus, depicted in Figure I.2. In this region, two forms of synaptic plasticity that 
depend on rapid dendritic protein synthesis are late-LTP (L-LTP) and metabotropic 
glutamate receptor group 1 (mGluR) LTD. mGluR-LTD is mediated by activation of 
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mGluR1/5 (G-protein-coupled receptors) with the agonist dihydroxyphenlglycine 
(DHPG) (Huber, Kayser et al. 2000).  
 
 
 
 
Figure I.2: Connection between synaptic plasticity and activity-dependent local 
translation in the hippocampus 
Left: The organization of the hippocampus. The Schaffer-collateral pathway is 
composed of axons from excitatory pyramidal neurons in the CA3 region (blue) that 
synapse on pyramidal neurons in CA1 (red). For long-term depression (LTD) 
experiments, the Schaffer-collateral pathway is stimulated and field potentials are 
recorded in the stratum radiatum (s. radiatum) of CA1, an area enriched for 
dendrites of CA1 pyramidal neurons. Middle: Treatment of hippocampal slices with 
dihydroxyphenlglycine (DHPG) induces LTD. The dashed line indicates the field 
excitatory postsynaptic potential (fEPSP) slope baseline before DHPG. The fEPSP 
slope is measured by a recording electrode placed in the s. radiatum of CA1 and 
reflects the excitatory response of the CA1 neurons from the CA3 neurons. After a 
brief application with DHPG, the fEPSP slope is persistently weaker and lasts for 
greater than 60 minutes. LTD is the difference between the pre-DHPG and post-
DHPG fEPSP. Right: Rapid, local translation in the dendrites of neurons is 
required for mGluR-LTD.  
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Synaptic plasticity depends on local, activity-dependent translation in neurons  
Neurons are highly polarized cells. Most neurons contain a cell body (soma), 1 
axon, and multiple, branched dendrites. Collectively, the neuronal processes make up the 
majority of the cytoplasm and are quite long compared to the soma (Holt, Martin et al. 
2019). In vertebrates, axons can extend hundreds of centimeters, and the average dendrite 
length of a pyramidal neuron is 13.5mm (Ishizuka, Cowan et al. 1995). Neuronal 
communication occurs at the synapse, where neurotransmitters are released from the 
presynaptic axon to activate receptors on the postsynaptic membrane. An excitatory 
pyramidal neuron receives input from roughly 54,000 synapses from different neurons, 
and the highly polarized nature of neurons poses a unique challenge in how neurons can 
rapidly and selectively respond to a specific, local stimulus (Holt, Martin et al. 2019). 
One such mechanism is through local protein synthesis that occurs in dendrites.  
Rapid protein synthesis in dendrites of neurons is required for mGluR-LTD and 
some forms of LTP. Kang and Schuman demonstrated that LTP induced by neurotrophic 
factors BDNF and NT-3 requires rapid protein synthesis; co-application with translation 
inhibitors anisomycin or cycloheximide blocked these forms of LTP (Kang and Schuman 
1996). To demonstrate a role for dendritic protein synthesis, Kang and Schuman micro-
dissected the cell body from the dendrites of the CA1 pyramidal neurons and still 
observed induction of LTP that was dependent on protein synthesis. Using similar 
experiments, Huber et al demonstrated that DHPG induces LTD (mGluR-LTD) in the 
same region of the hippocampus, and mGluR-LTD also requires rapid de novo protein 
synthesis in dendrites (Huber, Kayser et al. 2000).  
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The newly synthesized proteins required for synaptic plasticity are termed LTP or 
LTD proteins, and they underlie some of the local remodeling required for synaptic 
plasticity (Lüscher and Huber 2010). For example, microtubule-associated protein 1b 
(MAP1B) and activity-regulated cytoskeleton-associated protein (ARC) are synthesized 
in dendrites following mGluR-LTD, and both function to decrease AMPA receptor 
trafficking to postsynaptic membranes (Davidkova and Carroll 2007, Park, Park et al. 
2008, Waung, Pfeiffer et al. 2008). Dendritic translation of CaMKII is required for LTP, 
learning and memory, as demonstrated in a mouse model with impaired dendritic 
localization of CaMKII mRNA. In this mouse model, the dendrite localization signal of 
CaMKII mRNA was mutated, and this mouse had reduced LTP and had deficits in 
several protein-synthesis dependent behavioral tasks (spatial memory, fear conditioning, 
and object placement) (Miller, Yasuda et al. 2002). The identity of the plasticity proteins 
required for mGluR-LTD is largely unknown and remains a question of great interest. 
Recent advances in unbiased, deep-sequencing methods will allow for identification of 
these plasticity proteins.  
Translational regulation in synaptic plasticity 
Regulators of translation initiation in synaptic plasticity  
Translation is the process of producing proteins from mRNA by ribosomes. 
Because multiple inhibitors of the ribosome prevent synthesis of proteins required for 
synaptic plasticity, research has focused on translational regulation. Translational occurs 
broadly in 3 steps: initiation, elongation, and termination. Translation initiation is the 
process of the small ribosomal subunit binding to the mRNA and recognizing the 
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appropriate initiation codon. Translation initiation is the most complex step, involves 
multiple translation factors, and often considered the rate-limiting step of translation. The 
first step of initiation is the formation of the 43S preinitiation complex from the 40S and 
eIF2 ternary complex. The 43S complex then attaches to the mRNA in a 5′cap-dependent 
mechanism for most cellular mRNAs. The 43S scans along the 5′UTR of the mRNA. 
Upon reaching the initiation codon, the 60S subunit joins and translation factors are 
released to form the 80S ribosome (Jackson, Hellen et al. 2010). The ribosome then 
proceeds to the elongation stage of translation until it reaches a stop codon on the mRNA. 
Given the complexity of initiation, this step is regulated by many proteins and signaling 
cascades (Figure I.3). 
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Figure I.3: Major steps of cap-dependent translation initiation 
Depicted is a simplif ied model of translation init iation and its regulat ion by two 
major signaling pathways, the integrated stress response (ISR) and mTOR. A) The 
ternary complex is composed of eIF2, GTP, and the methionyl tRNA for init iation. 
The ternary complex and 40S ribosomal subunit joins to form the 43S preinit iation 
complex (PIC). B) mRNA activation is mediated by the cap-binding complex 
eukaryotic init iation factor (eIF) 4F. eIF4F (composed of the scaffold eIF4G, the 
cap-binding protein eIF4E, and the RNA helicase eIF4A) binds the 5 ′ m7G cap and 
poly(A) binding protein (PABP) to facil itate mRNA circularization. C) The PIC is 
recruited to the 5 ′ end of the activated mRNA by eIF4F, and after attachment to the 
mRNA, the PIC scans along the 5 ′UTR until i t reaches the init iation codon. During 
the ISR, phosphorylation of eIF2 by kinases reduces formation of the PIC to 
globally decrease translation init iation. mTOR signaling converges on 
phosphorylation of several eIFs to facil i tate mRNA activation and PIC scanning on 
the 5 ′UTR to globally promote translation init iation. Some eukaryotic init iation 
factors are excluded from the PIC for simplicity. 
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mTORC1 is a major regulator of translation initiation and required for multiple 
forms of synaptic plasticity. Neurotrophic factors and glutamate can activate the PI3K-
AKT and MEK/ERK signaling cascade to converge on TSC-Rheb-mTORC1. Activation 
of multi-unit kinase mTORC1 leads to phosphorylation of multiple downstream 
substrates to ultimately promote initiation (Figure I.4A). Two major mTORC1 substrates 
are the translation repressor eukaryotic translation initiation factor 4E-binding protein 
(4E-BP) and ribosomal protein S6 kinase beta-1 (S6K1). 4E-BP normally binds the cap-
binding protein eIF4E to impair cap-dependent translation, and phospho-4E-BP has 
decreased affinity for eIF4E. mTORC1 activates S6K1, leading to subsequent 
phosphorylation of ribosomal protein S6 (rpS6), eukaryotic elongation factor 2 kinase 
(eEF2K) and eukaryotic initiation factor 4B (eIF4B). Phospho-rpS6 is a widely used 
readout for mTORC1 activity, but the impact of phospho-rpS6 on translation is unclear. 
Phosphorylation of eEF2K and eIF4B broadly supports increased protein synthesis by 
promoting elongation and translation of mRNAs with long, structured 5′UTRs (Gandin, 
Masvidal et al. 2016).  
The role of mTOR signaling in synaptic plasticity and learning has been 
demonstrated through chemical inhibition of the pathway with rapamycin and mouse 
models of upstream regulators and downstream effectors. Rapamycin was initially 
discovered as an anti-fungal isolated from bacteria in soil from the island of Rapa Nui 
(Vézina, Kudelski et al. 1975). Rapamycin inhibits cell proliferation by blocking protein 
synthesis (Martel, Klicius et al. 1977, Singh, Sun et al. 1979). Rapamycin binds to FK506 
binding protein 12 (FKBP12) to predominantly inhibit mTORC1, but rapamycin can also 
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impair mTORC2 when applied in higher concentrations for longer duration (Sarbassov, 
Ali et al. 2006). Rapamycin impairs several forms of protein-synthesis dependent 
synaptic plasticity in the hippocampus, such as BDNF-induced LTP and mGluR-LTD 
(Tang, Reis et al. 2002, Hou and Klann 2004). Furthermore, injection of rapamycin into 
the hippocampus impairs protein-synthesis dependent long-term spatial memory 
formation in mice as measured by the Morris water maze, an assay where mice remember 
the location of a hidden platform based on visual cues (Dash, Orsi et al. 2006). 
Knockout mouse models of the major mTORC1 substrates 4E-BP2 and S6K1/2 
further support a role of mTORC1-dependent processes in synaptic plasticity and 
learning. mTOR and 4E-BP1/2 are present in the stratum radiatum (a region enriched for 
dendrites) of the hippocampus and synapses in cultured neurons (Tang, Reis et al. 2002). 
Eif4ebp2-KO mice also have altered synaptic plasticity (deficient L-LTP, enhanced 
mGluR-LTD) and deficits in protein-synthesis dependent forms of learning (long-term 
spatial learning and fear conditioning) (Banko, Poulin et al. 2005, Banko, Hou et al. 
2006). Mice lacking S6K1 or S6K2 have altered contextual fear memory and spatial 
memory (Antion, Hou et al. 2008). In addition, mice lacking TSC, the upstream inhibitor 
of mTOR, have learning deficits and evidence of increased S6K signaling consistent with 
mTOR hyperactivation (Ehninger, Han et al. 2008). 
mTORC1 can also increase the translation capacity of cells through increased 
protein synthesis of components of the translation machinery. A group of mRNAs 
sensitive to mTORC1 regulation is the 5′ terminal oligopyrimidine tract (TOP) mRNAs, 
which mostly encode ribosomal proteins and translation factors. Translation of TOP 
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mRNAs is regulated through phosphorylation of 4E-BP and the RNA-binding protein 
LARP1 (Thoreen, Chantranupong et al. 2012, Hong, Freeberg et al. 2017, Philippe, 
Vasseur et al. 2017). Dendritic translation of TOP mRNAs has been demonstrated 
following some forms of synaptic plasticity on a single gene level, such as eEF1A 
following mGluR5 signaling (Huang, Chotiner et al. 2005). However, it is unclear 
whether as a group the TOP mRNAs are translated during synaptic plasticity in an 
mTORC1-dependent manner. 
The experiments with rapamycin and knockout mouse models of mTORC1 
effectors support a role of mTORC1 signaling, 4E-BP, and S6K in translation of proteins 
required for synaptic plasticity and higher cognitive function. However, they do not 
exclude mTORC1 effects outside of translation (such as autophagy and lipogenesis) or 
mTORC1 independent effects of the 4E-BPs and S6K. Recent work has highlighted the 
importance of mTORC2, a more poorly characterized complex that cross talks with 
mTORC1 signaling to regulate the actin cytoskeleton. Somewhat contradictory to the 
experiments described earlier, Zhu et al argue that mTORC2, rather than mTORC1, is the 
major effector of mGluR-LTD (Zhu, Chen et al. 2018).  
Another major regulator of translation initiation required for synaptic plasticity is 
the integrated stress response (ISR) (Figure I.4B). Whereas mTOR signaling promotes 
translation to support cell proliferation, the ISR allows cells to adapt to a stress by 
inhibiting general protein synthesis while promoting translation of specific mRNAs 
(Hinnebusch 2005). The ISR converges on phosphorylation of the alpha subunit of the 
eIF2 ternary complex (eIF2α), which can be phosphorylated by one of four kinases 
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(GCN2, PERK, PKR, and HRI) in response to a variety of stressors. eIF2α is 
phosphorylated on Ser51, which impairs the formation of the ternary complex (eIF2, 
Met-tRNA, GTP) and subsequently reduces initiation for most mRNAs. Instead, the ISR 
promotes translation of mRNAs containing up-stream open reading frames (uORFs). 
Recent work has highlighted the role of the ISR in synaptic plasticity and higher 
cognitive function (Costa-Mattioli, Gobert et al. 2007, Di Prisco, Huang et al. 2014). 
mGluR5 signaling induces eIF2α phosphorylation and translation of a uORF-containing 
mRNA, Ophn1 (Di Prisco, Huang et al. 2014). eIF2α phosphorylation is required for 
mGluR-LTD, because chemical inhibition of eIF2α phosphorylation and a 
phosphorylation site mutation impairs mGluR-LTD.  
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Figure I.4: Overview of translation signaling pathways important for mGluR-LTD 
A) mGluR5 signaling activates mTORC1, which phosphorylates its major substrate 
S6K and 4E-BP. S6K phosphorylates multiple substrates, such as RPS6 and eIF4B, 
which promotes recruitment of the 43S preinit iation complex to mRNAs. Phospho-
4E-BP has lower affinity for eIF4E (the cap-binding protein) and promotes cap-
dependent translation. mRNAs that contain a terminal oligopyrimidine (TOP) tract 
immediately after the 5 ′ cap are particularly sensitive to mTORC1-dependent 
signaling. Collectively, mTORC1 signaling promotes global protein synthesis, 
whereas the chemical inhibitor rapamycin inhibits mTORC1-dependent translation. 
B) mGluR5 signaling activates the integrated stress response, which converges on 
phosphorylation of eIF2α  (part of the ternary complex required for init iation), by 
kinases. Phospho-eIF2α  decreases global protein synthesis, but promotes 
translation of mRNAs containing upstream open reading frames (uORFs). C) 
mGluR5 signaling activates eEF2K, the sole kinase that phosphorylates eukaryotic 
elongation factor 2 (eEF2). Phospho-eEF2 has decreased binding to ribosome and 
thus cannot promote ribosome translocation, leading to inhibit ion of global 
translation. Through a poorly characterized mechanism, phospho-eEF2 can also 
promote protein synthesis of poorly translated mRNAs required for mGluR-LTD. It 
is unknown how these multiple translation pathways interact to regulate synthesis 
of proteins required for mGluR-LTD. Positive regulators (green) and negative 
regulators (red) of translation indicated. Yellow circle with P represents 
phosphorylation events.  
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Regulation of translation elongation in synaptic plasticity  
Translational regulation has historically focused on initiation, but emerging 
studies reveals that translation elongation is also important for synaptic plasticity and 
appropriate brain function. Compared to translation initiation, translation elongation is a 
much simpler process. After initiation, eukaryotic elongation factor 1 (eEF1) bound to 
GTP brings the tRNA into the empty A site of the ribosome. eEF1-GTP is hydrolyzed to 
eEF1-GDP, and the growing nascent peptide is transferred to the A-site tRNA. Next, 
eukaryotic elongation factor 2 (eEF2) bound to GTP enters the A site to catalyze the 
transfer of the A-site peptidyl-tRNA to the P site. eEF2-GDP is released, and a round of 
elongation can repeat.  
Regulation of translation elongation occurs through phosphorylation of eEF2 on 
Thr56 within the GTP-binding domain, leading to global reduction of protein synthesis 
(Ryazanov, Shestakova et al. 1988, Price, Redpath et al. 1991). This phosphorylation 
event likely causes structural rearrangement of eEF2 to reduce binding to GTP and/or 
eEF2-GTP binding to ribosomes, leading to a roughly 10-100 times decreased affinity of 
eEF2 for the ribosomes without affecting GTP hydrolysis (Ryazanov, Shestakova et al. 
1988, Carlberg, Nilsson et al. 1990, Nilsson and Nygård 1991, Dumont-Miscopein, 
Lavergne et al. 1994). Eukaryotic elongation factor 2 kinase (eEF2K), a 
calcium/calmodulin-activated kinase (CaMKIII), phosphorylates eEF2, its sole substrate. 
eEF2K signaling is activated following different types of neuronal stimulation and is 
required for synaptic plasticity and learning and memory (Sutton et al 2007). mGluR-
LTD signaling leads to eEF2 phosphorylation, and mice lacking eEF2K have impaired 
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mGluR-LTD (Figure I.4C) (Park, Park et al. 2008). mGluR5/eEF2K signaling is required 
for translation of specific mRNAs, such as Arc and Bdnf, to support mGluR-LTD  (Park, 
Park et al. 2008, Verpelli, Piccoli et al. 2010). The exact mechanism of how phospho-
eEF2 can promote translation of specific mRNAs while inhibiting general protein 
synthesis is not well understood. One model proposes that slowing ribosome 
translocation can free up initiation factors to promote synthesis of inefficiently translated 
mRNAs (Walden and Thach 1986, Scheetz, Nairn et al. 2000). Further support comes 
from experiments with low dose cycloheximide, which can paradoxically increase 
translation of mRNAs (e.g. CaMKII, Arc) required for synaptic plasticity (Scheetz, Nairn 
et al. 2000, Park, Park et al. 2008).  
Recent work has highlighted the importance of translation elongation in the brain 
for neurodevelopmental and neurodegenerative disorders. Mutations in eukaryotic 
elongation factor 1A2 (eEF1A2) have been identified in patients with atypical Rett 
Syndome and patients with intellectual disability, autism, and seizures (Nakajima, 
Okamoto et al. 2015, Inui, Kobayashi et al. 2016). Regulation of mRNAs at elongation 
may allow for more rapid protein synthesis than initiation. A recent publication found 
that mRNAs with stalled and slow moving ribosomes in the hippocampus are highly 
enriched for neuronal function, such as axonal development and synaptic organization 
(Shah, Molinaro et al. 2020). Several elegant studies indicate that synaptic activity 
reactivates stalled ribosomes/granule complexes in dendrites. b-actin mRNA is unmasked 
in dendrites following a chemical LTP stimulation, suggesting that mRNA-ribosome 
complexes are stored in a repressed state until neuronal activation (Buxbaum and Singer 
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2014). Furthermore, Graber et al surprisingly found that harringtonine, a chemical that 
prevents the first round of elongation by blocking peptide bond formation without 
affecting downstream ribosomes, does not impair mGluR-LTD (Huang 1975, Fresno, 
Jiménez et al. 1977). This argues that at least some mRNAs required for mGluR-LTD are 
associated with stalled ribosomes downstream of the first round of elongation (Graber, 
Hebert-Seropian et al. 2013). 
Convergence of mGluR5 and mTOR signaling on ASD 
Given the heterogeneity and numerous genes associated with ASD, current 
studies are focused on identifying and understanding common pathways dysregulated 
across multiple forms of ASD. One such example is mTOR and mGluR5 signaling. 
Mutations in multiple upstream regulators of mTOR signaling and downstream effectors 
are high-risk autism mutations in humans (Figure I.5). TSC and PTEN are leading 
genetic disorders linked to syndromic ASD, and mutations in other components of mTOR 
signaling (MTOR, RHEB, NF1, S6K) have been identified in idiopathic ASD. 
Furthermore, altered mTOR signaling is observed in mouse models of other syndromic 
causes of ASD, including FXS, Rett Syndrome, and Phelan-McDermid syndrome.   
Multiple mouse models of ASD have altered mGluR-LTD. Huber et al first 
described that DHPG-induced mGluR-LTD is increased in a mouse model of FXS 
(Huber, Gallagher et al. 2002). Furthermore, the LTD in Fragile X mice was protein 
synthesis independent, because the translation inhibitor cycloheximide had no effect on 
LTD. Fragile X mice have increased protein synthesis in the brain, which correlates with 
increased PI3K/AKT/mTOR signaling (Sharma, Hoeffer et al. 2010). Multiple studies 
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suggest that elevated mTOR signaling contributes to dysregulated translation and FXS 
phenotypes. Protein synthesis in the brain, synaptic plasticity, and behavior are rescued in 
the FXS mouse model by chemical inhibition or genetic removal of S6K1 (encoded by 
Rps6kb1), a major mTORC1 substrate (Bhattacharya, Kaphzan et al. 2012). Although it is 
uncertain if the increased mTOR signaling is causative or a response in FXS mice, the 
Fmr1/Rps6kb1-KO mice suggests restoring mTORC1/S6K signaling rescues phenotypes 
of Rps6kb1-KO mice and male mice lacking Fmr1 (Fmr1-/y). Numerous FXS rescue 
mouse models have found a correlation between restoring protein homeostasis and 
correcting mGluR-LTD synaptic plasticity and autism-like behavior (Dölen, Osterweil et 
al. 2007, Auerbach, Osterweil et al. 2011, Bhattacharya, Kaphzan et al. 2012, Udagawa, 
Farny et al. 2013, Gross, Chang et al. 2015). Collectively, these experiments led to the 
“mGluR5 theory” of Fragile X Syndrome, where excessive mGluR5 signaling may drive 
the excessive protein synthesis underlying the altered synaptic plasticity (Bear, Huber et 
al. 2004). The mGluR theory of Fragile X Syndrome led to the development of mGluR5 
inhibitors for use in clinical trials. In addition, modulators of mGluR5 have shown 
promise in reducing seizures, ameliorating ASD-like behavior, and restoring protein 
homeostasis in a TSC mouse model of autism (Kelly, Schaeffer et al. 2018).  
Given that TSC is an inhibitor of mTOR signaling, one predicts that mice 
haploinsufficient in TSC would have increased mGluR-LTD similar to the FXS mice. 
Surprisingly, mice and rats with Tsc1 or Tsc2 deficiency consistently have decreased 
mGluR-LTD (von der Brelie, Waltereit et al. 2006, Auerbach, Osterweil et al. 2011). In a 
Tsc2 heterozygous mouse model (Tsc2+/-), this correlates with decreased protein 
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synthesis as measured by 35S-methionine labeling in the hippocampus (Auerbach, 
Osterweil et al. 2011). Rapamycin can restore mGluR-LTD to wild-type levels in Tsc2+/- 
mice, arguing that excessive mTOR signaling underlies the synaptic plasticity phenotype. 
The mechanism of how Tsc2+/- mice have decreased mGluR-LTD and protein synthesis 
is unknown. Regardless, a combined Tsc2+/- and Fmr1-/y mouse also restores protein 
synthesis in the brain and mGluR-LTD to wild-type levels (Auerbach, Osterweil et al. 
2011). These results support a model where a common set of mRNAs or pathways are 
altered in TSC and FXS. My project sought to identify the mRNAs whose translation is 
responsive to mGluR5 signaling and dysregulated in a mouse model of TSC by using 
ribosome profiling, an unbiased, high-resolution method to measure translation.  
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Figure I.5: mGluR5 and mTORC1 signaling to translation 
DHPG binding to mGluR5 leads to activation of MEK/ERK and PI3K/AKT signaling. 
ERK and AKT signaling converges to inhibit TSC (composed of TSC1/2), allowing 
for RHEB to activate mTORC1 (composed of core components mTOR, RAPTOR, 
mLST8, and other accessory proteins excluded for simplicity). mTORC1 is a 
serine/threonine kinase that inactivates the translational repressor 4E-BP and 
activates S6K1 to broadly promote cap-dependent protein synthesis. FMRP is 
degraded following mGluR5 signaling, relieving translational repression on its 
targets. The stars indicate mutations in genes associated with autism in humans 
(gene.sfari.org).  Positive regulators (green) and negative regulators (red) of 
translation are indicated. 
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Introduction 
Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by 
benign tumor growth in multiple organs and neuropsychiatric symptoms. Individuals with 
TSC have an increased incidence of seizures (~90%), intellectual disability (~50%), and 
autism (~50%) (Lipton and Sahin 2014).  Disrupted neuronal circuitry likely underlies 
many neuro-pathologies in TSC because individuals with an anatomically normal brain 
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can still present substantial developmental delay, intellectual disability, and autism. More 
direct evidence for impaired neuronal connectivity is derived from mouse models of the 
disorder, which display hyperexcitability, aberrant synaptic plasticity, and altered 
dendritic spine morphology (Tavazoie, Alvarez et al. 2005, Auerbach, Osterweil et al. 
2011). TSC is caused by loss-of-function mutations in TSC1 or TSC2; mutations in TSC2 
are more common and are responsible for the most severe symptoms. The TSC1/2 
proteins heterodimerize to form the tuberous sclerosis complex (TSC), a GTPase-
activating protein that inhibits Ras homology enriched in brain (Rheb) (Garami, 
Zwartkruis et al. 2003, Zhang, Gao et al. 2003). Rheb activates the mechanistic target of 
rapamycin (mTOR), a kinase that forms two biochemically distinct complexes: mTORC1 
and mTORC2 (Saxton and Sabatini 2017). mTORC1 regulates mRNA translation 
primarily via phosphorylation of 4E-BP and the kinase SK1 to phosphorylate rpS6 
(Brunn, Hudson et al. 1997, Gingras, Kennedy et al. 1998, Shaw and Cantley 2006). The 
less-characterized mTORC2 plays a role in actin cytoskeletal reorganization (Saxton and 
Sabatini 2017). Complete loss of TSC1 or TSC2 leads to excessive mTOR activity, and 
mutations in other components of the mTOR pathway are also linked to autism in humans 
such as PTEN, RHEB, and MTOR (O'Roak, Vives et al. 2012, Iossifov, O'Roak et al. 
2014). Thus, the mTOR pathway forms a highly connected signaling network linked to 
autism. Although pharmacological options are available for the treatment of seizures in 
individuals with TSC, there currently is no effective pharmacological treatment for the 
neuropsychiatric symptoms of intellectual disability and autism.  
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The mTOR pathway integrates signaling from various inputs to regulate synaptic 
plasticity and higher cognitive function. One example is metabotropic glutamate 
receptor-mediated long-term depression (mGluR-LTD), a form of synaptic plasticity that 
requires de novo protein synthesis (Huber, Kayser et al. 2000). The mGluR1/5 agonist 
dihydroxyphenylglycine (DHPG) stimulates group 1 metabotropic glutamate receptors to 
activate the PI3K/AKT/mTOR pathway, leading to translation of largely unidentified 
mRNAs required for mGluR-LTD (Hou and Klann 2004, Ronesi, Collins et al. 2012). 
Multiple mouse models of autism, such as TSC and Fragile X Syndrome, have altered 
hippocampal mGluR-dependent synaptic plasticity (Huber, Gallagher et al. 2002, 
Auerbach, Osterweil et al. 2011, Bateup, Takasaki et al. 2011, Auerbach, Osterweil et al. 
, Chévere-Torres, Kaphzan et al. 2012). Although experiments with rapamycin and 
inhibitors of protein synthesis suggest that excessive mTORC1-dependent translation 
drives the altered synaptic plasticity phenotype in TSC mice, other findings suggest a 
more complex picture. For example, Tsc2+/- mice have reduced hippocampal protein 
synthesis rates instead of the predicted excessive protein synthesis from mTOR 
hyperactivation (Auerbach, Osterweil et al. 2011). In addition, a recent study challenged 
the role of mTORC1 in hippocampal mGluR-LTD, arguing that mTORC2 is the major 
regulator of this form of synaptic plasticity (Park, Park et al. 2008, Zhu, Chen et al. 2018) 
but see (Hou and Klann 2004, Sharma, Hoeffer et al. 2010). MGluR1/5 signaling can also 
regulate translation factors to suppress global protein synthesis, such as phosphorylation 
of eukaryotic initiation factor 2 alpha and eukaryotic elongation factor 2 (eEF2), which 
are both necessary for mGluR-LTD (Park, Park et al. 2008, Di Prisco, Huang et al. 2014). 
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Although mGluR1/5 stimulation is known to promote translation of specific mRNAs 
(Waung, Pfeiffer et al. 2008), how translation is regulated in a transcriptome-wide 
manner by mGluR1/5 in either the normal or TSC brain is unknown.  
 Using a germline Tsc2+/- mouse model of TSC autism, we performed ribosome 
profiling, an unbiased whole transcriptome method that determines the number and 
positions of ribosomes on all mRNAs, and thus serves as a proxy for protein synthesis 
(Ingolia, Ghaemmaghami et al. 2009). Together with RNA-seq, ribosome profiling in 
wild-type and Tsc2+/- hippocampal slices under basal conditions and after induction of 
mGluR-LTD allows us to define posttranscriptional changes in gene expression in 
response to synapse activation (Huber, Kayser et al. 2000). We chose the Tsc2+/- mouse 
model because we strove to capture translational dysregulation that is reflective of TSC 
autism arising from TSC2 haploinsufficiency in humans. This mouse model displays 
excessive mTOR signaling, a well-characterized deficient mGluR synaptic plasticity, and 
alterations in social interactions and hippocampal-dependent learning tasks that are 
reversed by rapamycin treatment (Hernandez, Way et al. 2007, Ehninger, Han et al. 2008, 
Auerbach, Osterweil et al. 2011, Sato, Kasai et al. 2019). Using ribosome profiling, we 
identified changes in the Tsc2+/- hippocampus as well as following mGluR-LTD 
signaling. We also observed that mGluR1/5 stimulation induces a rapid increase in 
mRNA abundance, and targets of Fragile X Mental Retardation Protein (FMRP), an 
RNA-binding protein whose loss causes Fragile X Syndrome, are enriched in this group. 
mGluR stimulation also promotes phosphorylation of eukaryotic elongation factor 
(eEF2), which is deficient in Tsc2+/- mice. These animals have a reduced mGluR-LTD 
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and chemically mimicking phospho-eEF2 enhances this form of synaptic plasticity. Our 
results suggest a novel pathway of translational dysregulation in ribosome translocation 
(polypeptide elongation) that may contribute to altered translation and synaptic plasticity 
in TSC mice. 
Results 
Translational Profiling of the TSC hippocampus 
 The GTPase activating protein tuberous sclerosis complex (TSC) is an upstream 
but indirect repressor of mTOR, a kinase which forms the multi-subunit complex 
mTORC1 to stimulate translation in response to a number of signaling inputs including 
activated group I metabotropic glutamate receptors (e.g., mGluR5). mGluR5 activation 
leads to long term depression (LTD), a protein synthesis-dependent form of synaptic 
plasticity frequently examined at hippocampal Schafer collateral-CA1 synapses (Huber, 
Kayser et al. 2000). To model TSC, a multi-organ disorder characterized by autism, 
epilepsy, and intellectual disability, we generated mice lacking one copy of the Tsc2 
gene, which will henceforth be referred to as the Tsc2+/- mouse.  
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To detect subtle changes in translation, we turned to ribosome profiling, a high-
resolution and unbiased whole transcriptome method for determining the number and 
positions of ribosomes on mRNA. When combined with RNA-seq, the ratio of ribosome 
occupancy over input mRNA yields translational efficiency (TE) (Ingolia, 
Ghaemmaghami et al. 2009). Changes in TE are often used as a proxy for protein 
synthesis, where an increased TE suggests increased translation rates and protein 
production. However, changes in TE may not always reflect protein output when 
ribosome elongation or mRNA levels are altered. Hippocampal slices, some of which 
were treated with dihydroxyphenylglycine (DHPG) for 5 min to induce LTD, were lysed 
in the presence of cycloheximide to prevent ribosome run-off, digested with RNases A 
and T1, and the 80S monomers containing ~30nt ribosome protected fragments (RPFs) 
were collected by ultracentrifugation (Figure II.1). The isolated RPFs were appended 
with primers for library construction and sequencing (>10 million uniquely mapped 
Figure II.1: Schematic of 
experimental design  
RNA-Seq and ribosome profi l ing were 
performed from CA1-enriched 
hippocampal slices of Tsc2+/-  and 
wild-type littermate controls. Slices 
were treated with DHPG (100µM, 
5min) or artif icial cerebrospinal f luid 
(vehicle) and then processed for RNA-
Seq and ribosome profi l ing. Slices 
from 6 mice were pooled per genotype 
and condition, and 3 biological 
replicates were performed. RPF= 
ribosome protected fragment. 
	
 
34	
34 
reads; libraries were strongly correlated with each other; Pearson’s R>0.95).   
Figure II.2A shows relative expression levels of the differentially expressed (DE) 
genes with altered levels of RNA and RPFs from the hippocampal slices of the Tsc2+/- 
mice and their littermate controls under basal (unstimulated) conditions that pass a 
significance cutoff of FDR < 0.1. Tsc2 was the top differentially expressed mRNA at 
both the RNA and RPF level, confirming the validity of our approach (Figure II.2B). The 
DE mRNAs with altered levels of RNA and RPF in Tsc2+/- had little overlap with each 
other (n = 5). The ratio of RPF to RNA yields translational efficiency (TE), but because 
changes in TE do not distinguish between RPF and RNA effects and because few RNAs 
passed statistical cutoff for changes in TE (log2FC), we considered RNA and RPF 
changes separately. 
We observed enrichment for terms related to the GABA-receptor complex, 
mitochondrial membrane, and myelin sheath for RPFs that were Up regulated in the 
Tsc2+/- brain (Figure II.2C). No GO terms were enriched in the Down regulated RPF 
group, likely due to the small number of genes. An altered excitatory/inhibitory balance 
is frequently observed in ASD, and the increased translation of GABA-A related proteins 
might be a compensatory response to the increased hyperexcitability observed in Tsc2+/- 
mice (Bateup, Johnson et al. 2013, Potter, Basu et al. 2013, Nelson and Valakh 2015, 
Antoine, Langberg et al. 2019, Basu, Riordan et al. 2019). Altered translation of 
mitochondrial membrane proteins is consistent with the role of mTOR-dependent 
translational control of mitochondrial-related mRNAs and reports of mitochondrial 
dysfunction in Tsc2-deficient cultured neurons (Morita, Gravel et al. 2013, Ebrahimi-
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Fakhari, Saffari et al. 2016). The abnormalities in myelination in TSC patients and 
function of TSC/mTOR in myelination and function of oligodendrocytes (Tsai and Sahin 
2011, Peters, Struyven et al. 2019) may be due to translational control of myelin sheath 
proteins. 
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Figure II.2: Ribosome profiling of Tsc2+/- hippocampal slices reveals RNA and RPF 
dysregulation 
A) Heatmaps show differentially expressed genes with altered levels of RNAs (left) 
and RPFs (right) in Tsc2+/- compared to WT under basal conditions. Relative gene 
expression is shown for each mRNA (row), and each column represents a biological 
replicate (n=3) for RNA (DE=109, FDR < 0.1) and RPFs (DE=99, FDR < 0.1). B) 
Normalized count plots of RNA (top) and RPF (bottom) levels for Tsc2  are shown 
(Wald-test for genotype comparison with BH correction. RNA: log2FC -0.52, padj < 
7.4e-32; RPF log2FC -0.70, padj < 2.4e-22). C) GO term enrichment of mRNAs with 
upregulated RPFs in Tsc2+/- compared to WT (padj < 0.05).  
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Dysregulation of 5′ terminal oligopyrimidine (TOP) mRNAs in Tsc2+/- 
The major downstream substrate of TSC is mTOR, which controls specific and 
global translation (Figure II.3, top). mRNAs that contain a 5′ terminal oligopyrimidine 
motif (TOP), which generally encode components of the translational machinery, and 
mRNAs with long structured 5′UTRs are especially sensitive to mTOR regulation 
(Svitkin, Pause et al. 2001, Holz, Ballif et al. 2005, Thoreen, Chantranupong et al. 2012, 
Gandin, Masvidal et al. 2016). TSC/mTOR also regulates general translation through 
phosphorylation and dephosphorylation events such as those that occur on 4E-BP, eIF4B, 
rpS6, and eEF2 (Redpath, Foulstone et al. 1996, Browne and Proud 2004, Raught, 
Peiretti et al. 2004, Holz, Ballif et al. 2005). Elevated mTOR signaling contributes to 
various behavioral and synaptic plasticity phenotypes in the brains of TSC mice as 
evidenced by their rescue by treatment with the mTOR inhibitor rapamycin (Ehninger, 
Han et al. 2008, Auerbach, Osterweil et al. 2011). We found that the TOP mRNAs had 
mildly increased RPFs, but as a group, they had increased TE that is primarily driven by 
decreased RNA levels (Figure II.3, bottom). mTOR can also promote initiation of non-
TOP mRNAs that have long, structured 5′UTRs via eIF4E and eIF4A (Gandin, Masvidal 
et al. 2016). However, we find no difference in the 5′UTR lengths or predicted secondary 
structures in the up- and down-regulated RPFs (Figure II.4A). To assess whether 
signaling events usually associated with mTOR activation occur in Tsc2+/- hippocampus, 
we examined phospho-mTOR and phospho-rpS6, which are indirect downstream 
substrates of TSC. Changes in the basal levels of phospho-mTOR are undetectable in 
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TSC hippocampus, and there is only a trend towards increases in phospho-rpS6 (Figure 
II.4B), similar to previous reports (Potter, Basu et al. 2013).  
 
 
 
Figure II.3: Dysregulation of TOP mRNAs in Tsc2+/- 
Top) Schematic depicting mTOR control of translation. mTOR controls mRNA-
specific translation via 5 ′ terminal oligopyrimidine (TOP) motifs or long, structured 
5 ′UTRs. mTOR controls global init iation and elongation via 
phosphorylation/dephosphorylation of 4E-BP, rpS6, and eEF2. Bottom) Density 
plots depict distribution of mRNA, RPF, and translation efficiency (TE) expression 
changes (Tsc2+/-/WT log2FC) for TOP mRNAs (n=68) compared to non-TOP 
mRNAs. Wilcoxon rank-sum test with correction by Bonferroni method. 
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Figure II.4: Lack of unique 5′UTR features in dysregulated RPFs from Tsc2+/- 
A) Density plots depict the distribution of the length (left) and minimal free energy 
(MFE) (right) of the 5 ′UTR of Down and Up RPFs in Tsc2+/- compared to all mRNAs. 
ns = non-significant, Wilcoxon rank-sum test with correction by Bonferroni method. 
B) The levels of phosphorylated and total rpS6 (left) and mTOR (right) as 
determined by western blots of fresh, whole hippocampus from wild-type and 
Tsc2+/- l i t termate (n= 5 animals, ns = non-significant, unpaired t-test). Levels of 
total rpS6 are not significantly altered between Tsc2+/- and wild-type hippocampus 
(88+/- 13% of WT; n = 5 mice/genotype; unpaired t-test). 
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Because we did not identify specific mRNA features in the mRNAs and RPFs 
dysregulated in Tsc2+/- mice, we wondered if the mRNA-specific dysregulation may arise 
by decreased global protein synthesis as previously demonstrated in these mice 
(Auerbach, Osterweil et al. 2011). Mills and Green proposed the “ribosome 
concentration” hypothesis to explain how a modest reduction in global protein synthesis 
rates from decreased ribosome levels might differentially affect translation of mRNAs 
with low and high initiation rates (Mills and Green 2017). Based on this model, 
translation of most mRNAs would be unaffected, but mRNAs with high initiation rates 
may have increased protein output because of decreased inhibitory ribosome crowding. 
Conversely, mRNAs with low initiation rates, such as those with long, structured 
5′UTRs, uORFs, internal ribosome entry sites, or poor Kozak sequences, would have 
decreased protein output because these mRNAs are poor substrates for translation 
initiation. Because Tsc2+/- mice have a roughly 25% decrease in global protein synthesis 
through an unknown mechanism, we used the “ribosome concentration” model as an 
intellectual framework for interpreting our results (Auerbach, Osterweil et al. 2011). We 
approximated initiation by calculating TE from wild-type basal slices, which will be 
referred to as hippocampal TE. The Up RNAs in Tsc2+/- had a low hippocampal TE 
compared to all (Figure II.5, left). We find that mRNAs with Down RPFs in Tsc2+/- had a 
low hippocampal TE and the Up RPFs had a high hippocampal TE compared to all 
(Figure II.5, middle). These results suggest that in Tsc2+/- mice, poorly translated mRNAs 
are reduced even further while highly translated mRNAs become more robustly 
translated, consistent with the “ribosome concentration” hypothesis (Figure II.5, right). 
	
 
41	
41 
Finally, Figure II.6 shows transcript features that correlate with hippocampal TE. 
Consistent with another study, hippocampal TE is correlated with GC content of the 
CDS, 3′UTR, and 5′UTR and also CDS length (Chan, Mugler et al. 2018). 
 
 
 
 
  
 
Figure II.5: Correlation of hippocampal TE with degree of dysregulation in Tsc2+/- 
Density plots depict distribution of the hippocampal TE for the up and down RNA 
(left) and RPF (middle) groups in Tsc2+/-/WT compared to all genes (one-tailed 
Kolmogorov-Smirnov test, pvalues indicated in plots). The hippocampal TE is 
calculated from the average of wild-type basal slices as the ratio of RPF to RNA. 
Right: Schematic depiction of how loss of Tsc2 could affect translation of lowly and 
highly translated mRNAs. 
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Figure II.6: Transcript features of hippocampal TE 
Pearson correlation coefficient was computed for pairs of transcript features 
including translation efficiency (TE), coding length and GC content (CDS), 5 ′ 
untranslated region length and GC content (5 ′UTR), 3 ′ untranslated region length 
and GC content (3 ′UTR), and RNA abundance (TPM, transcripts per mill ion). Red 
indicates a positive correlation, and blue a negative correlation. Gray indicates a 
correlation of identical parameters. p < 0.05 for all correlation coefficients. 
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FMRP binding targets are altered in opposite directions in TSC and FXS mice 
Loss of the RNA-binding protein Fragile X Mental Retardation Protein (FMRP) 
leads to Fragile X Syndrome (FXS).  FMRP and TSC2 bidirectionally regulate mGluR-
LTD and behavior, suggesting they might regulate similar mRNAs. In support of this, a 
combined TSC/FXS mouse rescues deficits in synaptic plasticity and learning to wild-
type levels compared to the single mouse mutants (Auerbach, Osterweil et al. 2011). 
Given the rescue paradigm of the FXS and TSC mouse, we determined if FMRP targets 
are altered in Tsc2+/- mice. We used a list of FMRP targets identified by CLIP (crosslink 
and immunoprecipitation) in CA1 pyramidal neurons, where FMRP targets were 
stratified into 3 groups based on binding strength: stringent (n=327), high (n=938), and 
low (n=1330) binding targets (Sawicka, Hale et al. 2019). FMRP targets are enriched (p < 
5.3e-8) in the mRNAs altered in TSC, and as a group, they have decreased TE that is 
driven by increased RNA levels that correlate with stringency of FMRP binding (Figure 
II.7A). FMRP targets have no change in RPFs in TSC (Figure II.7A, middle). 
Interestingly, the FMRP targets are decreased in the FXS mouse (Fmr1-/y) at the RNA 
and RPF level, which is also correlated with stringency of FMRP binding (Figure 
II.7B)(Ceolin, Bouquier et al. 2017, Sawicka, Hale et al. 2019, Shu, Donnard et al. 2019, 
Shah, Molinaro et al. 2020). Because FMRP binding targets were dysregulated in Tsc2+/-, 
we determined if FMRP protein levels were altered in Tsc2+/-. FMRP levels were 
unaltered in Tsc2+/- (Figure II.7C), suggesting that altered FMRP levels are not 
responsible for the increased RNA levels of FMRP targets in Tsc2+/- mice. This 
bidirectional change in FMRP target mRNAs could be linked to the TSC/FXS mouse 
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rescue paradigm and reveals a complex interaction of TSC2 and FMRP in steady-state 
regulation of mRNAs in the hippocampus.  
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Figure II.7: FMRP binding targets are regulated by TSC2 and FMRP in opposing 
directions 
Empirical Cumulative Distribution Function (ECDF) of RNA (left), RPF (middle), and 
TE (right) log2FC expression changes of FMRP binding targets compared to non-
target mRNAs in A) Tsc2+/-/WT and B) Fmr1-/y/WT mice. FMRP binding targets are 
stratif ied into 3 groups based on binding stringency. Wilcoxon rank-sum test with 
Bonferroni correction. Data of hippocampal slices of Fmr1-/y mice from Shah et al 
(Shah, Molinaro et al. 2020) and FMRP binding targets from Sawicka et al 
(Sawicka, Hale et al. 2019). C) The levels of FMRP as determined by western blots 
of fresh, whole hippocampus from wild-type and Tsc2+/- l i t termates. n= 5 animals, 
ns = non-significant, unpaired t-test. 
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mGluR5 signaling induces a rapid RNA and translational response 
mGluR-LTD is regulated by TSC, so to determine the identity of mGluR-
stimulated translation of specific RNAs during LTD, we performed ribosome profiling 
and RNA-seq on hippocampal slices following 5 minutes of DHPG treatment (Huber, 
Kayser et al. 2000, Park, Park et al. 2008, Waung, Pfeiffer et al. 2008). Figure II.8A 
shows that RNA (DE=241, FDR < 0.01) and RPF (DE=212, FDR < 0.05) levels undergo 
rapid changes in response to the mGluR1/5 agonist DHPG. DHPG-responsive RNAs and 
RPFs largely did not overlap (n=5). Our DHPG-responsive translational changes in area 
CA1 do not overlap with those identified by polysome RNA-seq in cultured cortical 
neurons, which we attribute to different sample types and methodologies (Di Prisco, 
Huang et al. 2014). Gene set enrichment analysis reveals that GO terms related to G 
protein-coupled receptor activity, synaptic membranes, and the endoplasmic-reticulum 
membrane are enriched in the upregulated RNA and RPFs, and helicase activity is 
enriched in the down-regulated RNAs and RPFs (Figure II.9 and Figure II.10 
respectively). Some GO terms are unique to the RNA or RPF changes. For example, the 
RNAs upregulated following DHPG are enriched for transcription-related functions, and 
the DHPG translational response is enriched for terms related to the lysosome. Some 
examples of DHPG-responsive mRNAs and RPFs that are high confidence SFARI autism 
genes (https://gene.sfari.org, score 1 or 2) are shown in Figure II.8B for Shank3, Dlg4, 
and Ache. Dlg4 mRNA encodes PSD-95, which has increased mRNA and protein levels 
following DHPG-mGluR signaling (Zalfa, Eleuteri et al. 2007). Nrsn1 mRNA encodes a 
neuron-enriched regulator of vesicle transport, which is translationally repressed 5 
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minutes after a hippocampus-dependent learning task (Cho, Yu et al. 2015). Translational 
repression of Nrsn1 mRNA during learning may be a requirement for this cognitive 
process as evidenced by the observation that its overexpression leads to deficits in object 
location and contextual fear memory. Because we did not observe immediate early genes 
(c-fos, Arc, and Egr1) in our list of differentially expressed RNAs, we infer that the rapid 
changes in RNA levels are likely due to alterations in RNA destruction and not 
transcription. 
Because FMRP is regulated by and required for mGluR1/5 signaling to translation 
(Muddashetty, Nalavadi et al. 2011, Nalavadi, Muddashetty et al. 2012, Niere, Wilkerson 
et al. 2012, Huang, Ikeuchi et al. 2015), we determined if FMRP mRNA targets are 
responsive to this form of synaptic plasticity. FMRP binding targets are enriched in the 
DHPG-responsive DE RNAs (p < 1.8e-44) and RPFs (p < 5.0e-9). As a group, the FMRP 
targets have increased RNA levels following mGluR signaling that correlate with 
stringency of FMRP binding (Figure II.8C, left). FMRP targets have decreased RPFs 
following synaptic stimulation, and an overall decrease in TE that correlates with FMRP 
binding stringency (Figure II.8C, middle and right). Therefore, mGluR stimulation 
regulates RNA levels and translation of FMRP target mRNAs. 
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Figure II.8: mGluR signaling induces rapid RNA and RPF changes in wild-type 
hippocampal slices 
A) Heatmaps of mRNAs (left) and RPFs (right) that are responsive to DHPG 
(100µM, 5min) in wild-type hippocampal slices. Red and blue color represents 
relative gene expression for individual mRNAs (row); each column represents a 
biological replicate (n= 7 for RNA-Seq, n= 8 for ribosome profi l ing), Differentially 
expressed RNA (DE=241, FDR < 0.01) and RPFs (DE=212, FDR < 0.05).  B) 
Examples of DHPG responsive mRNAs (top) or RPFs (bottom) are shown with 
normalized RNA and RPF counts from DESeq2. P values are from the output of 
DESeq2 analysis (Wald-test with BH correction). C) Empirical Cumulative 
Distribution Function plots (ECDF) of RNA (left), RPF (middle), and TE (right) 
expression changes in DHPG/Basal (log2FC) of FMRP binding targets compared to 
non-target mRNAs. FMRP binding targets are stratif ied into 3 groups based on 
binding stringency. Wilcoxon rank-sum test with correction by Bonferroni method. 
p-values are indicated in the plot legend. 
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Figure II.9: Gene set enrichment analysis of mGluR-responsive RNAs 
Gene set enrichment analysis of GO terms enriched (padj < 0.05) in DHPG/Basal 
RNAs for molecular function (top) and cellular compartment (bottom). Gene lists 
were ranked by wild-type DHPG/Basal expression changes (log2FC) and p-value. 
GO terms are separated by enrichment in either upregulated (increased) or 
downregulated (decreased) RNAs. 
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Figure II.10: Gene set enrichment analysis of mGluR-responsive RPFs 
Gene set enrichment analysis of GO terms enriched (padj < 0.05) in DHPG/Basal 
RPFs for molecular function (top) and cel lular compartment (bottom). Gene lists 
were ranked by wild-type DHPG/Basal expression changes (log2FC) and p-value. 
GO terms are separated by enrichment in either upregulated (increased) or 
downregulated (decreased) RPFs. 
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mGluR-induced translational dysregulation in TSC 
Tsc2+/- mice have deficient mGluR-LTD, so we determined whether the RNA and 
translational response after DHPG is altered. We lacked sufficient statistical power to 
detect genotype-dependent alterations in the DHPG response in Tsc2+/- slices with their 
littermate controls. Instead, we compared the genes altered in Tsc2+/- from Figure II.2 and 
the DHPG-responsive genes in wild-type from Figure II.8 and found a statistically 
significant overlap for the RNAs (n=23, p < 4.3e-21) and RPFs (n=20, p < 3.8e-18) 
(Figure II.11A). Interestingly, 16 of the 23 RNAs that overlap between Tsc2+/- and 
mGluR1/5-stimulated are FMRP mRNA targets. No GO terms were enriched in the 
overlapping list, likely due to the small number of genes. Heatmaps of the relative 
expression levels of the overlapped mRNAs and RPFs in Figure II.11A shows that most 
of the upregulated mRNAs and RPFs in unstimulated Tsc2+/- slices appear to have a 
deficient DHPG response compared to wild-type slices Figure II.11B. Our results suggest 
that some mRNAs and RPFs that are elevated in unstimulated Tsc2+/- slices cannot 
respond to DHPG. 
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Figure II.11: Some mRNAs altered in unstimulated Tsc2+/- slices do not respond to 
DHPG-mGluR signaling 
A) Venn diagrams showing overlap between Tsc2+/- dysregulated RNAs and DHPG-
responsive RNAs (top) and Tsc2+/- dysregulated RPFs and DHPG-responsive RPFs 
(bottom). Gene overlap test was performed with a Fisher’s exact test and a 
background size of expressed RNAs used in DE analysis. B) Heatmaps of mRNAs 
(left) and RPFs (right) that overlap from (A). Red and blue color represents relative 
gene expression for individual mRNAs (row), and each column represents a 
biological replicate of l i ttermates (n= 3).  
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Signaling to eukaryotic elongation factor 2 is altered in the Tsc2+/- hippocampus 
The sequencing results of the Tsc2+/- slices under basal and DHPG conditions 
suggest there is a deficiency in the ability of DHPG to regulate translation in the Tsc2+/- 
mice. To determine whether mGluR1/5 signaling to translational control was altered in 
Tsc2+/-, hippocampal slices were treated with DHPG followed by western blotting for 
several well-established downstream substrates of mGluR activation. Figure II.12A-B 
shows that under basal conditions, phosphorylated (phospho) ERK or AKT were 
unaffected by loss of one allele of Tsc2. In response to DHPG treatment, phospho-ERK 
levels were similarly elevated in WT and Tsc2+/- slices, consistent with other 
observations (2, 42).  DHPG did not induce phospho-Akt in either WT or Tsc2+/- slices. 
Because both mTOR and mGluR5 signaling regulate phosphorylation of eukaryotic 
elongation factor 2 (eEF2), we determined whether signaling to eEF2 could be altered. In 
wild-type slices, DHPG treatment robustly induces eEF2 phosphorylation (Figure 
II.12C). Surprisingly, Tsc2+/- slices have elevated phospho-eEF2 basally, and DHPG 
treatment fails to induce eEF2 phosphorylation. Total levels of eEF2 are unchanged in 
Tsc2+/- at basal (106 ±6% of WT; n = 19 mice; n.s.; 2way ANOVA, posthoc Sidak’s test) 
and following DHPG treatment (WT 101.7 ±8.02%, Tsc2+/- 114.4 ±9.69%, n=19, n.s.; 
2way ANOVA, posthoc Sidak’s test). 
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Figure II.12: Deficient mGluR1/5-regulated signaling to translation elongation in 
Tsc2+/- mice 
A-C) The levels of phosphorylated (P) and total (T) ERK (A), AKT (B), and eEF2 
(C) in CA1-enriched hippocampal slices from wild-type and Tsc2+/-mouse 
littermates as determined by western blots under basal or DHPG-treatment 
condition (100µM; 5min). *p < 0.05, **p< 0.01; ***p< 0.001; 2 way ANOVA, posthoc 
Sidak’s test, n=11-19 mice/genotype, 4-5 slices per drug condition/mouse. 
Asterisks below brackets indicate an effect of DHPG on phosphoprotein levels 
within genotype. Asterisks above brackets indicate effects between genotypes.  
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eEF2 is a GTP-dependent elongation factor that promotes transfer of peptidyl-
tRNAs from the A to P site of the ribosome. Phosphorylation of eEF2 on threonine 56 
prevents it from binding to ribosomes, leading to inhibition of translation elongation 
(Carlberg, Nilsson et al. 1990). Somewhat counterintuitively, eEF2 kinase and its 
phosphorylation of eEF2 are necessary for mGluR-induced synthesis of proteins required 
for LTD (Park, Park et al. 2008). Global inhibition of translation elongation, such as 
through phospho-eEF2 or cycloheximide (a chemical inhibitor of ribosome 
translocation), may promote synthesis of poorly translated mRNAs by liberating rate-
limiting translation factors (Park, Park et al. 2008, Acevedo, Hoermann et al. 2018, 
Sossin and Costa-Mattioli 2019). Thus, we determined if the mRNAs responsive to 
mGluR-LTD signaling are enriched for poorly translated mRNAs by using hippocampal 
translation efficiency as described earlier. We find that the Up RNA group after DHPG 
treatment has low basal translation efficiency compared to unchanged mRNAs and the 
Down mRNA group has high basal translation efficiency (Figure II.13, left). For the 
translational response, the Up RPF group after DHPG-mGluR signaling has high basal 
translation efficiency compared to other mRNAs, whereas the Down RPF group had the 
same translation efficiency as the unchanged mRNAs (Figure II.13, middle). Because 
DHPG-mGluR signaling may reduce ribosome translocation via phospho-eEF2, it is 
possible that at least some of the mRNAs with increased RPFs are associated with stalled 
ribosomes, in which case they would have decreased translation. Because FMRP binding 
targets are enriched in the DHPG-mGluR responsive Up mRNA group, we predicted that 
FMRP targets are also lowly translated in the hippocampus. Indeed, FMRP binding 
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targets have low basal translation efficiency compared to non-targets (Figure II.13, right). 
Interestingly, the strength of FMRP binding negatively correlates with basal translation 
efficiency where the most stringent FMRP targets have lower basal translation efficiency 
compared to the low and high stringency groups. Taken together, these observations 
suggest that mGluR5 signaling increases expression of mRNAs that are lowly translated, 
such as FMRP binding targets. 
  
 
Figure II.13: Correlation of hippocampal TE with mGluR5-responsive mRNAs and 
FMRP binding targets 
Empirical Cumulative Distribution Function (ECDF) plots of hippocampal TE for the 
Up and Down RNAs (left) and RPFs (middle) in DHPG/Basal compared to all 
genes. Right: ECDF plot of hippocampal TE for FMRP binding targets compared to 
non-target mRNAs. FMRP binding targets are stratif ied into 3 groups based on 
binding stringency. Wilcoxon rank-sum test with correction by Bonferroni method. p 
values are indicated in the plot legend. 
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Because Tsc2+/- slices have a deficient phospho-eEF2 response to DHPG 
treatment, we hypothesized that ribosome elongation is excessive during mGluR 
signaling in Tsc2+/- and may contribute to deficient mGluR-LTD. We used a low 
concentration of cycloheximide (75 nM), which inhibits ribosome elongation by binding 
to the E-site of the ribosome to prevent eEF2-mediated translocation (Schneider-Poetsch, 
Ju et al. 2010). This concentration of cycloheximide restored mGluR-LTD in eEF2K 
knockout mice without affecting mGluR-LTD in WT mice (Park, Park et al. 2008). We 
induced mGluR-LTD with DHPG in hippocampal slices and tested the effects of low 
dose cycloheximide (75nM) to inhibit ribosome elongation. While there were no main 
effects of genotype or treatment overall on LTD magnitude, we observed a significant 
interaction of genotype*treatment (Figure II.14). With posthoc pairwise comparisons, 
there was strong trend for cycloheximide to enhance mGluR-LTD in Tsc2+/- (veh:  83± 
2% of baseline; cycloheximide; 75± 5%) but not WT mice (veh:  74± 2% of baseline; 
cycloheximide; 77± 3%). In vehicle, mGluR-LTD in Tsc2+/- was less than WT as 
previously reported (Auerbach, Osterweil et al. 2011). Our data suggest that the 
deficiency of mGluR1/5 induced P-eEF2 and suppression of translation elongation in 
Tsc2+/- mice limits LTD magnitude and this can be reinstated by pharmacological 
inhibition of ribosome elongation.  
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Figure II.14: Low dose cycloheximide enhances LTD in Tsc2+/- 
Left: Time course demonstrating that brief DHPG application (100µM; 5min) 
induces long-term synaptic depression (LTD) of f ield (f) EPSP slopes in WT 
hippocampal slices that is unaffected by low doses of cycloheximide (45-60min 
pretreatment, 75 nM; n = 12 and 15 slices; 6-7 mice/condition). Middle : In Tsc2+/- 
mice pre-treatment with low dose cycloheximide enhances LTD magnitude (n= 10 
and 15 slices; 7 mice/condition). Plotted are group averages of fEPSP slope (mean 
± SEM) normalized to pre-DHPG baseline as a function of t ime.  Inset:  Example 
fEPSP from baseline and during LTD (55-60 min post DHPG).  Scale = 
0.5mV/10msec. Right: LTD magnitude, measured at 55-60 min post-DHPG 
application in vehicle and cycloheximide in each genotype. There is a significant 
interaction of cycloheximide and Tsc2  genotype (F(1,47) = 5.197, p < 0.05; LMM). 
With posthoc pairwise comparisons, there is a strong trend for cycloheximide to 
enhance LTD in Tsc2+/-  mice (veh:  83± 2% of baseline; cycloheximide; 75± 5%; n = 
15 and 10 slices from 4 mice/treatment; F(1,23) = 5.445, # p= 0.058; LMM) but not 
WT mice (veh:  74± 2% of baseline; cycloheximide; 77± 3%; n = 11 and 15 slices 
from 6 and 5 mice, respectively/treatment; F(1,24) = 3.819, p= 0.14; LMM). In 
vehicle, LTD is reduced in Tsc2+/- mice in comparison to WT, but not in low dose 
cycloheximide. (*p< 0.05; **p< 0.01). Veh = vehicle, CHX = cycloheximide.  
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Discussion 
Using ribosome profiling and RNA-seq, we identified changes in ribosome 
footprint number and RNA levels in Tsc2+/- hippocampal slices and following mGluR-
LTD. Our experimental design captures changes from multiple cell types, which is 
reflective of the tissue complexity of the hippocampus. We found translation of myelin-
related mRNAs increased in Tsc2+/- mice, which are predominantly found in 
oligodendrocytes. The tissue complexity may explain why we did not capture translation 
of known DHPG-induced mRNAs Arc and Map1b, which are translated following DHPG 
treatment in dendrites of excitatory neurons (Waung, Pfeiffer et al. 2008, Graber, Hebert-
Seropian et al. 2013). 
In complete loss of TSC1 or TSC2 models, there is clearly excessive mTOR 
activity that leads to widespread changes in translation (Bilanges, Argonza-Barrett et al. 
2007). However, mTOR hyperactivation is not always as obvious in Tsc1 and Tsc2 
heterozygote models in the brain (Potter, Basu et al. 2013). Using a Tsc2+/- model, we do 
not observe signs of mTOR hyperactivation by western blot of phosphorylated rpS6 and 
mTOR in the hippocampus. Regardless, we find evidence of disrupted global mRNA 
translation by increased TE of TOP mRNAs and elevated levels of phosphorylated eEF2. 
The TOP mRNAs, the most well-studied TSC/mTOR translational targets, have increased 
TE from predominantly decreased RNA and increased RPF levels. The decreased RNA 
levels of the TOP mRNAs are surprising, given that one predicts increased expression of 
TOP mRNAs from mTOR hyperactivity from loss of TSC2. There could be two 
possibilities to explain this observation. This may be an example of translational 
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buffering to maintain homeostasis of proteins encoded by TOP mRNAs, where RNA 
levels decrease to offset the increase in ribosome occupancy (McManus, May et al. 
2014). Alternatively, the decreased RNA levels of TOP mRNAs may be reflective of the 
altered signaling to phospho-eEF2, which is increased and opposite of the direction that is 
predicted by activation of mTORC1-S6K-eEF2K signaling in Tsc2+/- animals (Redpath, 
Foulstone et al. 1996, Browne and Proud 2004). mTOR-independent signaling pathways 
can regulate the TOP mRNAs, such as eEF2K/eEF2 signaling and the RNA-binding 
protein LARP1, which stabilizes mRNA levels of TOP mRNAs. Decreased ribosomal 
protein levels can activate a stress response that increases eEF2 phosphorylation 
(Gismondi, Caldarola et al. 2014). LARP1 deficiency can also decrease TOP mRNA 
levels, activate a ribosomal stress response, and increase eEF2K/eEF2 signaling 
(Gentilella, Moron-Duran et al. 2017). Consequently, the increased in basal 
phosphorylated eEF2 in Tsc2+/- mice may occur via other effectors to eEF2K, such as 
increased intracellular Ca2+ and mGluR1/5 signaling (Wang, Li et al. 2001, Park, Park et 
al. 2008). 
Our finding of increased basal levels of phospho-eEF2 is consistent with the 
observation of decreased protein synthesis rates in hippocampal slices of Tsc2+/- mice 
(Auerbach, Osterweil et al. 2011).  eEF2K/eEF2 signaling is required for mGluR-LTD, 
learning and memory, and maintaining an appropriate excitatory/inhibitory balance in the 
brain, all of which are disrupted in the Tsc2+/- animals (Sutton, Taylor et al. 2007, Park, 
Park et al. 2008, Gildish, Manor et al. 2012, McCamphill, Farah et al. 2015, Weng, Chen 
et al. 2016, Heise, Taha et al. 2017, Antoine, Langberg et al. 2019). A further direction of 
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inquiry is to determine whether genetic or chemical reduction of eEF2K activity can 
improve molecular, synaptic plasticity, and behavioral phenotypes of the TSC mice. 
Our study suggests a more complex role of translational dysregulation in the 
Tsc2+/- hippocampus outside of simple mTORC1-rpS6 hyperactivation. Given the many 
downstream substrates of mTOR, it is possible that some of the mRNA and translational 
alterations observed in Tsc2+/- are through mTORC1-dependent processes outside of 
translation (e.g. autophagy, lipogenesis) or mTORC2. Our results also highlight the 
importance of maintaining appropriate gene dosage in modeling TSC and other 
mTORopathies such as PTEN in the context of ASD, where only 1 allele is usually 
mutated in patients. 
Tsc2+/- mice have decreased global protein synthesis in the hippocampus, and 
consistent with this observation, we observed dysregulated eEF2K/eEF2 signaling basally 
and following activation of DHPG-mGluR signaling in Tsc2+/- mice. Thus, we used the 
“ribosome concentration” and eEF2 phosphorylation model to determine if TE correlates 
with translational changes in Tsc2+/- mice and following DHPG-mGluR5 signaling. The 
“ribosome concentration” model was originally proposed to explain the seemingly 
mRNA-specific effects arising from decreased protein synthesis in ribosomopathies, a 
group of disorders with mutations in ribosomal proteins that manifest with cell-type 
specific features. Using mathematical modeling and assuming initiation as the rate-
limiting step of translation, the “ribosome concentration” hypothesis proposed that 
mRNAs with poor initiation rates (low TE) have decreased protein output with reduced 
global protein synthesis, whereas mRNAs with high initiation rates (high TE) have 
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increased protein output. Here, we observe a trend where in Tsc2+/- mice, inefficiently 
translated mRNAs have decreased translation and efficiently translated mRNAs have 
increased translation that is consistent with the “ribosome concentration” (Figure II.5). 
mGluR-LTD depends on phosphorylation of eEF2, and phosphorylated eEF2 is 
proposed to increase protein synthesis of poorly translated mRNAs by freeing up rate-
limiting translation factors while repressing translation of most mRNAs (Walden and 
Thach 1986, Scheetz, Nairn et al. 2000, Park, Park et al. 2008). Surprisingly, during 
DHPG-mGluR1/5 signaling, TE correlates more with transcript level changes rather than 
translation changes, and FMRP binding targets have low TE compared to all genes 
(Figure II.13). These data are consistent with the model that phospho-eEF2 increases the 
abundance of poorly translated mRNAs during mGluR-DHPG signaling, however at the 
transcript level instead of translation. The link between phospho-eEF2 and regulation of 
mRNA abundance is unknown, but one possibility is that slowing ribosomes may protect 
some mRNAs from degradation by decay factors (Chan, Mugler et al. 2018). Another 
possibility is that phospho-eEF2 is not directly responsible for the mRNA level changes, 
but instead is part of a parallel mGluR5 signaling pathway that converges on a regulator 
of mRNA abundance, such as FMRP. Several recent studies have supported a role of 
FMRP in modulating stability of its targets through N6-methyladenosine modification of 
the mRNA and codon optimality (Zhang, Kang et al. 2018, Shu, Donnard et al. 2020). TE 
is a complex value that includes multiple mRNA features that correlates with efficiency 
of translation initiation (5′UTR length and structure) and/or mRNA stability (GC content 
and codon optimality). Thus, the difference in the correlation of TE with the mRNA 
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abundance changes following mGluR5 signaling and the translational changes in Tsc2+/- 
mice may reflect different mechanisms that converge on either mRNA turnover or 
translation. 
RNA-seq reveals that mGluR activation induces a rapid response in both 
increased and decreased mRNA levels. Because translation is often linked to RNA 
stabilization/destabilization, this mGluR response could be linked to this process (Richter 
and Coller 2015). The decrease in specific mRNAs may be the result of heightened rates 
of degradation, which could be the consequence of mGluR-dependent upregulation of 
microRNAs (Olde Loohuis, Ba et al. 2015). For mRNAs that increase, there may be a 
constant rate of mRNA turnover in hippocampal tissue, and mGluR activation could lead 
to mRNA stabilization through regulation of translation or microRNA dissociation 
(Muddashetty, Nalavadi et al. 2011). The DHPG-mGluR responsive mRNAs are highly 
enriched for FMRP targets and genes encoding synaptic proteins. For example, our study 
and that of Zalfa et al (Zalfa, Eleuteri et al. 2007) found that levels of PSD-95 mRNA 
(Dlg4), an FMRP target, increase after mGluR activation in cultured neurons and is 
regulated by interaction with a microRNA (Muddashetty, Nalavadi et al. 2011). The 
observation that DHPG results in decreased RPFs and TE on FMRP target mRNAs 
suggests they have reduced translation. This would be a surprising finding based on 
previous findings that DHPG rapidly stimulates the synthesis of proteins encoded by 
FMRP target mRNAs such as Map1b, Arc, EF1a and PSD-95 (Waung, Pfeiffer et al. 
2008, Waung and Huber 2009, Muddashetty, Nalavadi et al. 2011, Graber, Hebert-
Seropian et al. 2013). Therefore, decreased RPF and TE may not always indicate reduced 
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synthesis of protein. Some evidence indicates that FMRP stalls or slows ribosome 
translocation, and mGluR stimulation regulates translation elongation through FMRP and 
eEF2 phosphorylation (Park, Park et al. 2008, Darnell, Van Driesche et al. 2011, 
Nalavadi, Muddashetty et al. 2012, Shah, Molinaro et al. 2020). Thus, for some mRNAs, 
the observed decrease in RPF or TE on FMRP target mRNAs in response to DHPG may 
be a consequence of enhanced ribosome movement that reflects increased protein 
synthesis.  
Recent work has revealed regulation of translational elongation as critical for 
multiple forms of protein-synthesis dependent synaptic plasticity (Scheetz, Nairn et al. 
2000, Park, Park et al. 2008, Verpelli, Piccoli et al. 2010, McCamphill, Farah et al. 2015). 
DHPG-induced mGluR1/5 signaling via ERK is normal in the Tsc2+/- hippocampus, 
which mainly feeds into regulation of translation initiation (Roux and Topisirovic 2018). 
Instead, signaling to ribosome translocation (polypeptide elongation) is altered in Tsc2+/- 
and a low dose cycloheximide enhances mGluR-LTD in these mice. Furthermore, we 
find evidence for a mechanism of occlusion via eEF2 phosphorylation in Tsc2+/-, where 
some of the mRNAs and RPFs increased in Tsc2+/- mice appear to no longer respond to 
DHPG, consistent with the higher basal levels of phospho-eEF2 and the deficient 
phospho-eEF2 response following DHPG. Our work suggests a novel mechanism of 
translational dysregulation in Tsc2+/- and mGluR synaptic plasticity through signaling to 
ribosome elongation. 
A combined Tsc2+/- and Fmr1-/y mouse rescues phenotypes in synaptic plasticity 
and contextual fear conditioning in each other, yet the mechanism of this rescue paradigm 
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has remained elusive. In Tsc2+/- and following DHPG-mGluR signaling, FMRP binding 
targets have decreased TE from increased RNA levels; in Fmr1-/y, RNA levels of FMRP 
targets are instead decreased. This bidirectional alteration of FMRP binding targets 
suggest a mechanism for the opposing changes in synaptic plasticity and rescue paradigm 
of the Tsc2+/-/Fmr1-/y mice. Because total FMRP protein levels are unchanged in Tsc2+/-, 
the dysregulation of FMRP binding targets may be through alternate pathways in 
transcription, mRNA stability, and/or translation. It is unknown if the increased transcript 
levels of FMRP binding targets are from transcription or post-transcriptional processes, 
and additional experiments utilizing RNA polymerase II ChIP-seq and metabolic RNA 
labeling combined with RNA-seq can distinguish contributions from RNA transcription, 
processing, and turnover. Furthermore, mRNAs that are dysregulated in Tsc2+/- are 
enriched for DHPG-mGluR responsive mRNAs and many of these overlapping mRNAs 
are FMRP binding targets. These results reveal a complex interaction of TSC2 and FMRP 
in steady state and mGluR regulation of distinct mRNA subclasses (Figure II.15).   
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Figure II.15: Model of altered eEF2 signaling and FMRP binding targets in Tsc2+/-  
Schematic showing DHPG-mGluR5 induction of eEF2K signaling to phosphorylation 
of eEF2 in hippocampal slices. Left: In WT slices, DHPG-mGluR5 signaling leads 
to increased levels of phospho-eEF2, which presumably slows ribosome transit and 
promotes expression of lowly translated mRNAs, such as FMRP binding targets, 
required for mGluR-LTD. Right: Under basal conditions in Tsc2+/- sl ices, eEF2 is 
already phosphorylated by eEF2K, and elevated phospho-eEF2 correlates with 
increased mRNA abundance of lowly translated mRNAs and FMRP binding targets. 
DHPG-mGluR5 signaling does not further increase eEF2 phosphorylation in Tsc2+/- 
sl ices. Tsc2+/- sl ices may have excessive ribosome transit during mGluR signaling 
that contributes to deficient mGluR-LTD. 
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Limitations 
We anticipated that loss of 1 copy of Tsc2 would result in widespread but perhaps 
subtle gene expression changes, consistent with other mouse models of autism. As such, 
we used a p-adjusted cut-off of 0.1 for the genotype comparison. One limitation of the 
interpretation of our ribosome profiling results is that we identified altered signaling to 
ribosome movement in Tsc2+/- and following mGluR-LTD signaling. Thus, changes in 
ribosome density may not a priori reflect changes in protein synthesis. Multiple mouse 
models of autism have altered mGluR-LTD signaling, but evidence of altered mGluR-
LTD in humans with autism has yet to be established.  
Conclusions 
By performing RNA-seq and ribosome profiling on a mouse model of Tsc2+/- 
autism and mGluR-LTD, we identified changes in FMRP binding targets that suggest a 
molecular basis for bidirectional regulation of synaptic plasticity and behavior by TSC2 
and FMRP. Our study also suggests that altered mGluR-regulated translation elongation 
contributes to impaired synaptic plasticity in Tsc2+/- mice. 
 
Material and methods 
Animals 
Germline Tsc2+/- mice were generated by crossing CMV-Cre (B6.C-Tg(CMV-
cre)1Cgn/J) (JAX stock number: 006054) with Tsc2flox mice (JAX Stock 
number:027458). F1 were then bred on the C57BL/6J background to obtain WT and 
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Tsc2+/- mice. Animals were given ad libitum access to food and water and reared on a 12-
hour light-dark cycle.  All experiments were approved by the Institutional Animal Care 
and Use Committee at University of Texas Southwestern and conducted in accordance 
with the National Institutes of Health Principles of Laboratory Animal Care. 
 
Hippocampal slice preparation 
Acute hippocampal brain slices were prepared from P30-40 wild-type (WT) and Tsc2+/- 
littermates as described previously (Jakkamsetti, Tsai et al. 2013). Briefly, mice were 
anesthetized with ketamine (125 mg/kg)/xylazine (25 mg/kg) and transcardially perfused 
with chilled (4°C) sucrose dissection buffer containing the following (in mm): 2.6 KCl, 
1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 5 MgCl2, 212 sucrose, and 10 dextrose aerated 
with 95% O2/5% CO2. Transverse hippocampal slices (400µm) were obtained on a Leica 
VT1200S slicer. CA3 was cut off to avoid epileptogenic activity induced by DHPG. 
Slices were recovered for 3-4 hours and maintained at 30°C in artificial cerebral spinal 
fluid (ACSF) containing the following (in mM): 119 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 
26 NaHCO3, 1 NaH2PO4 and 11 D-glucose aerated with 95% O2/5% CO2 to pH 7.4. 
Slices were then treated with cycloheximide (100 µg/ml) in ACSF, 4°C, snap-frozen on 
dry ice/EtOH bath, and stored at -80°C. Alternatively, hippocampal slices were treated 
with DHPG (100 µM) (Tocris) or artificial cerebrospinal fluid (ACSF, vehicle) for 5 min. 
For the cycloheximide experiments, hippocampal slices were pre-treated with 75nM 
cycloheximide for 45-60 minutes. At the end of the incubation, CA1 was dissected out, 
snap frozen in a dry ice/ethanol bath, and stored at -80 C. Some hippocampal slices were 
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prepared without removing CA3 and used for RNA-seq and ribosome profiling 
experiments as indicated below (batch 1-5). 
 
Electrophysiology recordings 
For all recordings, slices were submerged and perfused with ACSF at 2.5–3.5 ml/min (30 
± 1°C). Field potentials (FPs) and EPSCs were evoked by stimulation of the Schaffer 
collateral pathway with a concentric bipolar tungsten electrode. Field potentials were 
recorded with a glass electrode (1 MΩ) filled with ACSF placed in the stratum radiatum 
of CA1. Test stimuli were delivered every 30 s and a stable baseline was obtained at 
∼50% of the maximum FP amplitude. 
 
Western Blotting 
Western blotting was performed on whole hippocampus homogenates or on CA1 
hippocampal slices, where indicated, and as previously described (Ronesi, Collins et al. 
2012). CA1 hippocampal slices were lysed with lysis buffer (50 mm Tris, pH 7.4, 120 
mm NaCl, 50 mm NaF, and 1% Triton X-100, containing Protease Inhibitor Mixture, 
Sigma #P8340; and phosphatase inhibitor mixture 2 and 3, Sigma #P5726 and #P0040). 
Samples were homogenized using brief (5–10 s) pulses of sonication with an ultrasonic 
cell disruptor until lysates were clear. Lysates were then centrifuged at 15,700 ×g for 10 
min at 4°C, the pellets discarded, and protein levels in the supernatant were measured 
using a Pierce BCA kit. After SDS-PAGE, proteins were transferred onto PVDF 
membranes. After blocking with 5% BSA in 1× TBS, 0.05% Tween 20 for 1 h, 
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membranes were incubated with the following primary antibodies in blocking buffer 
overnight at 4°C: The following antibodies were used in this study: S6 Ribosomal Protein 
(Cell Signaling, #2217), Phospho-S6 Ribosomal Protein Ser235/236 (Cell Signaling, 
#4856), Akt (Cell Signaling, #9272), Phospho-Akt Ser473 (Cell Signaling, #4060), 
p44/42 MAPK (Erk1/2) (Cell Signaling #9102), Phospho-p44/42 MAPK (Erk1/2) 
Thr202/Tyr204 (Cell Signaling, #9101), eEF2 (Cell Signaling, #2332), Phospho-eEF2 
Thr56 (Cell Signaling, #2331), mTOR (Cell Signaling, #2983), Phospho-mTOR Ser2448 
(Cell Signaling, #2971), FMRP (DSHB, 2F5-1), Glyceraldehyde-3-Phosphate 
Dehydrogenase (Millipore, #MAB374), actin (Millipore, #MAB1501). After three 10min 
washes of 1× TBS, 0.05% Tween 20, membranes were incubated with the appropriate 
HRP-conjugated secondary antibodies in 5% milk in 1× TBS, 0.05% Tween 20 for 1 hr at 
room temperature. After three 10min washes of 1× TBS, 0.05% Tween 20, the 
membranes were developed using ECL. For comparison of phosphorylated protein levels 
across conditions or genotypes, immunoreactive phosphorylated protein bands were 
normalized to total protein levels from the same slice homogenates (e.g., P-ERK/ERK), 
each of which was first normalized to loading control (either GAPDH or actin where 
indicated). 
 
Sample preparation for RiboSeq and RNA-Seq 
Hippocampal slices from 6 mice were pooled, lysed in polysome buffer (as above but 
with the addition of 100ug/mL cycloheximide, 25U/mL Turbo Dnase I, 1X EDTA-free 
protease inhibitor, 1% NP-40), and triturated with a 25G needle 10 times. Following 
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placement on ice for 10 minutes, the lysate was centrifuged 2,000g for 10min at 4°C, and 
the supernatant collected and centrifuged again for a 20,000g for 10min at 4°C. This 
supernatant was collected and the RNA concentration measured using the Qubit RNA HS 
Assay kit (Invitrogen, #Q32852). One-fourth of the lysate was saved for RNA-seq 
libraries (~1ug of RNA) and the remainder (~3.5ug) was treated with 11.3ug of RNase A 
(Ambion, #AM2270) and 1410U of Rnase T1 (Thermo Fisher Scientific, #EN0542), 
which corresponds to a ratio of ~3ug Rnase A/375U Rnase T1 per ug of input RNA. The 
Rnase treatment was carried out at 25°C for 30min with gentle shaking and the digest 
stopped by placement on ice and the addition of 2.5uL of SuperRNaseIn (Invitrogen, 
#AM2696). The lysate was layered over a linear 10-50% sucrose gradient (prepared with 
polysome buffer supplemented with 1mM DTT and 100ug/mL CHX) and centrifuged at 
35,000rpm for 2.5 hours at 4°C in a SW41 rotor. The 80S monosome fractions were 
identified by continuous A260 monitoring and pooled for RNA extraction by Trizol LS. 
To aid in RNA recovery of low concentration samples, 20ug glycogen was added to all 
precipitation steps. A total of 3 biological replicates per genotype and treatment were 
made from hippocampal slices (CA1 enriched, batch 6-8) from Tsc2+/- and their wild-
type littermate mice. Wild-type slices had a total of 8 biological replicates for RiboSeq 
and 7 for RNA-Seq (batch 1-5 from hippocampal slices with CA3, batch 6-8 from CA1 
enriched). 
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Library Preparation 
All RiboSeq libraries were prepared as previously described (Heyer, Ozadam et al. 2015). 
RiboZero Gold (Illumina, #MRZG12324) was used to deplete rRNA for RiboSeq 
libraries. The purified 80S monosome mRNA fragments were resolved on a 15% Tris-
borate urea gel (National Diagnostics, #EC-833) and ribosome protected fragments 
between 26nt and 34nt were recovered from the gel by the crush-soak method overnight 
in RNA extraction buffer (300mM NaOAc pH5.5 1mM EDTA 0.25% SDS) at 25°C with 
constant horizontal rotation. The RNA was then precipitated and the purified RNA was 
dephosphorylated with PNK enzyme (NEB, #M0201S) and ligated to preadenylated 
adaptors (IDT) using T4RNL2Tr.K227Q ligase (NEB, #M0351L). Reverse transcription 
(RT) was performed using SuperScript III (Invitrogen, #18080-044) in a modified 1X 
First Strand synthesis buffer without MgCl2 (50 mM Tris–HCl, pH 8.3, 75 mM KCl). 
Primers containing a 5nt barcode and 8nt unique molecular identifier (UMI) were used 
for RT. After RT, the RNA was hydrolyzed with a final concentration of 0.1N NaOH for 
20min at 98°C. The cDNA was resolved on a 10% TBU gel and the 130-140nt band was 
selected. The cDNA was eluted from crushed gel pieces overnight in DNA extraction 
buffer (300mM NaCl, 1mM EDTA, 10mM Tris pH8.0) at 25°C with constant horizontal 
rotation. The cDNA was circularized using CircLigase (Epicentre, #CL4115K) and 
depleted of tRNA and rRNA using biotinylated anti-sense probes (IDT) and Dynabeads 
MyOne Streptavidin C1 (Invitrogen, #65001). To determine the optimal number of PCR 
cycles, a test PCR was performed using the KAPA library amplification kit (Kapa 
Biosystems, #KK2611). The final PCR product was run on an 8% TBE gel, and the 180-
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190nt bands were selected. The PCR product was eluted overnight in DNA extraction 
buffer as described earlier. 
Batch 1-5 RNA-Seq libraries were prepared using RiboZero to deplete rRNA and 
then fragmented with 2X alkaline fragmentation solution (2 mM EDTA, 10 mM Na2CO3, 
90 mM NaHCO3, pH ~ 9.3) at 95°C for 15min to yield ~140nt fragments. The 
fragmented RNA was separated on a 10% TBU gel, and those migrating between 100 and 
150nt were selected. RT products were separated on a 10% TBU gel and the 200-250nt 
band was selected. The final PCR product was run on an 8% TBE gel, and the 260-300bp 
band was selected. The size distribution of the final libraries was confirmed by Fragment 
Analyzer (UMMS Molecular Biology Core). Batch 6-8 RNA-Seq libraries were prepared 
using NEXTflex poly(A) beads (Bioo Scientific, #512980) and the NEXTFlex Rapid 
Directional qRNA-Seq kit (Bioo Scientific, # NOVA-5130-03D) according to 
manufacturer’s instructions. 
The final libraries were purified using AMPure XP beads (Beckman Coulter, 
#A63880) Purified libraries were quantified by qPCR using KAPA Library 
Quantification kit (Kapa Biosystems, #KK4835) and were pooled to equimolar ratios. 
Libraries were sequenced on a NextSeq 500/550 High Output Kit v2 (Illumina, #FC-404-
2005) as 75bp single-end runs on a NextSeq500 sequencer. 
 
RiboSeq pipeline and read mapping 
The individual samples were separated based on 8nt barcodes using custom scripts. 
Cutadapt (1.7.1) was used to remove the adapter 
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(TGGAATTCTCGGGTGCCAAGGAGATCGGAAGAGCGGTTCAGCAGGAATGCC
GAGACCG). The reads were then uploaded to the UMass Bioinformatics Core Dolphin 
platform for mapping (https://www.umassmed.edu/biocore/introducing-dolphin/). The 
reads were quality filtered using Trimmomatic (0.32) and then mapped to the rRNA and 
tRNA reference using bowtie2 (2.1.0). The rRNA and tRNA unmapped reads were kept 
and then mapped to mm10 using TopHat2 (2.0.9). Only uniquely mapped reads were 
kept, and PCR duplicates were marked based on UMI sequence and a custom script. 
samtools (0.019) was used to keep uniquely mapped reads without duplicates. For gene 
level quantification of RiboSeq, RSEM/1.2.11 was used to align cleaned, unique reads to 
the RefSeq mm10 CDS with the first and last 30nts removed to avoid quantifying 
initiation and termination peaks. For RNA-seq libraries, reads were aligned to the entire 
mm10 transcriptome. Counts from RSEM were batch corrected using the Combat 
function in sva (3.24.4). Batch-corrected counts were used for DESeq2 (1.26.0) to 
identify differentially expressed genes for RNA and RiboSeq libraries. Normalized RNA 
and RPF counts from DESeq2 were used for generating plots. To generate relative 
expression heatmaps of differentially expressed genes, regularized log2 transformation 
was applied to read counts for variance stabilization. The row mean was subtracted from 
individual row value to yield relative expression level of each gene. anota2seq (1.0.1) 
was used to calculate expression changes in TE (log2FC) using the Relative Log 
Expression (RLE) for normalization. 
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GO term, GSEA, and gene overlap analysis 
GO term enrichment was performed using the R package clusterProfiler (3.14.0)(Yu, 
Wang et al. 2012). For GSEA, mRNAs were ranked by their log2FoldChange and pvalue 
from DESeq2 output. P values were corrected with Benjamini-Hochberg, and terms with 
padj < 0.05 were considered enriched. Gene overlap analysis was performed using the R 
package GeneOverlap (1.22.0). The genes past filtering from DE analysis were used as 
the background.  
  
Transcript feature analysis 
Gene features were obtained from the UCSC Genome Browser using RefSeq annotations. 
For downstream transcript analysis, the most abundant isoform from the RSEM output of 
the RNA-Seq libraries was selected. ViennaRNA/RNAFold (2.1.6h) was used to 
calculate the minimal free energy of the 5′UTR.  
 
Hippocampal TE calculation and rolling mean plots 
The average CA1 translational efficiency (TE) was calculated by taking the ratio of RPF 
to RNA reads per kilo-base per million mapped reads (RPKM) from 3 wild-type basal 
samples aligned to the mm10 CDS reference without the initiation and termination peak. 
For consistent TE calculations, mapping to the CDS for RPF and RNA was used, and 
transcripts longer than 300nt and RPKM > 5 were included. 
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Quantification and statistical analysis 
An unpaired Wilcoxon rank-sum test with Bonferroni correction was used to compare 
means between groups unless indicated otherwise in the text and figures. A one-tailed 
Kolmogorov-Smirnov test was used in Figure II.5. An unpaired t-test was used for 
quantification of western blots in Figure II.4B and Figure II.7C. Western blot results in 
Figure II.12A-C were analyzed with a 2 way, repeated measures ANOVA.  Factors are 
DHPG treatment and genotype, repeated measures are basal and DHPG levels in the 
same mouse.  n= # mice.  Posthoc Sidak’s multiple comparison test was performed to 
determine statistical significance for specific comparisons, reported in the figure. For 
analysis of LTD results in Figure II.14, we performed a linear mixed-effects model 
(LMM) statistic, whereby the variability due to random effects (animal, slice) was taken 
into account, allowing for direct measurement of genotype and/or treatment effects 
(Nakagawa and Hauber 2011). Mixed-effects models were fitted using IBM SPSS 
package. Fixed factors were genotype, treatment, genotype*treatment; repeated/random 
effects were slices nested within subject (mouse). 
 
Code availability 
Custom scripts for generating plots will be available upon request to the lead contact.  
 
Availability of data and materials 
The RNA-seq and Ribo-seq datasets supporting the conclusions of this article are 
available in the GEO Database repository: GSE144539.  Publically available datasets 
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analyzed in the current study are from the following GEO Database repository: Shah et 
al, 2020: GSE143333 
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Preface 
 A.H.	and	J.D.R.	designed	the	experiments.	A.H.	performed	all	the	experiments,	
analysis,	and	writing	with	input	from	J.D.R.		
Introduction 
Fragile X Related Protein (FMRP) is a RNA-binding protein (RBP) whose loss 
causes Fragile X Syndrome, the leading monogenetic cause of intellectual disability. 
Multiple studies have shown that the vast majority of FMRP interacts with ribosomes, 
possibly to slow ribosome movement on mRNA to repress translation. Thus the FMRP-
ribosome complex is likely critical for translational repression of mRNAs linked to 
synaptic function and autism, yet their identities are largely unknown. This project seeks 
to identify these mRNAs using selective ribosome profiling. 
Fragile X Mental Retardation Protein (FMRP) is an RNA-binding protein (RBP) 
with roles in mRNA stability, localization, and translational repression of targets 
important for neurodevelopment. FMRP contains 2 canonical RNA-binding domains, the 
K homology (KH) domains and the arginine and glycine rich (RGG) box. Cross-linking 
immunoprecipitation (CLIP) experiments to identify direct targets of FMRP revealed a 
surprising binding pattern for FMRP.  Unlike most RBPs that bind a specific motif in the 
untranslated regions (UTRs), FMRP exhibits broad binding to the CDS of roughly 1000 
mRNAs linked to synaptic function and autism (Darnell, Van Driesche et al. 2011, Tabet, 
Moutin et al. 2016, Maurin, Lebrigand et al. 2018, Sawicka, Hale et al. 2019, Li, Shin et 
al. 2020). CLIP experiments find that FMRP binding targets are enriched for ACUK and 
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WGGA motifs and G-quadruplex containing mRNAs (secondary structures that form in 
guanine-rich mRNAs). (Ascano, Mukherjee et al. 2012, Maurin, Lebrigand et al. 2018, 
Li, Shin et al. 2020). However, the ACUK and WGGA motifs are found in all mRNAs, 
so it is unclear how FMRP mediates specificity through these sequences. There is also 
little consensus as to whether these cis-elements are important for FMRP regulation since 
the ACUK/WGGA sequence and G-quadruplex structure had no effect on FMRP 
translational inhibition in vitro (Chen, Sharma et al. 2014).  
A possible explanation of FMRP’s binding preference for CDS and mechanism of 
translational repression is through an interaction with the ribosome. Most of FMRP 
associates with polyribosomes (Khandjian, Corbin et al. 1996, Feng, Warren et al. 1997, 
Stefani 2004), possibly as part of a stalled ribosome-mRNA complex (Darnell, Van 
Driesche et al. 2011). FMRP-bound ribosome complexes are resistant to puromycin, an 
aminoacyl-tRNA analogue that promotes premature chain termination of elongating 
ribosomes, suggesting that FMRP-associated ribosomes are not in an elongation state or 
that FMRP prevents the action of puromycin. After ribosome runoff, FMRP binding 
targets co-sediment in lighter polysome fractions in multiple FMRP loss of function 
models (Darnell, Van Driesche et al. 2011). In addition, ribosome transit rate is faster in 
Fmr1-/y hippocampal slices (Udagawa, Farny et al. 2013). Collectively, these experiments 
suggest that FMRP can block ribosome translocation to repress translation of its target 
mRNAs. Multiple studies have suggested that FMRP can directly associate with 
ribosomes via the 60S subunit (Khandjian, Corbin et al. 1996, Siomi, Zhang et al. 1996, 
Ishizuka, Siomi et al. 2002). In vitro binding assays demonstrates that exons 13 and 14 of 
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human FMRP can directly interact with the 60S in the absence of mRNA (Siomi, Zhang 
et al. 1996). Exons 13 and 14 are predicted to form a coiled coil structured, which 
mediates protein-protein interaction. In addition, a study found that recombinant 
drosophila FMRP (dFMRP) can directly bind the ribosome with high affinity (KD ~ 
20nM) to repress translation in vitro (although this study concludes that the N-terminal 
KH domains mediate FMRP’s interaction with the ribosome) (Chen, Sharma et al. 2014). 
Chen et al solved a cryo-EM structure of dFMRP directly bound to the ribosome, which 
indicates that dFMRP binds the ribosome intersubunit space to occlude P-site aminoacyl-
tRNAs and elongation factors from binding. However, it is unclear how a translationally-
repressed ribosome can accommodate both FMRP and tRNA in the P-site. The authors 
proposed a model where the RNA-binding properties of the RGG box of FMRP mediate 
the mRNA-specificity of the FMRP-ribosome complex. 
The cryo-EM structure of FMRP and the ribosomes raises an interesting question 
of whether this complex can recognize specific mRNAs similar to or distinct from FMRP 
binding targets. FMRP has numerous functions, and while CLIP studies have identified 
FMRP binding targets, the functional consequences of FMRP binding to mRNA cannot 
be inferred by simply identifying binding partners. In addition, CLIP experiments may 
miss certain populations of FMRP targets: UV crosslinking efficiency is poor and FMRP-
CLIP targets are biased to identifying long, highly abundant transcripts (Ouwenga 2015). 
Conventional ribosome profiling can be used to identify translational dysregulation in 
Fmr1-/y mice, a mouse model of FXS. However, FMRP binds roughly 5% of brain 
mRNAs with diverse functions. Thus, conventional ribosome profiling makes it 
	
 
82	
82 
challenging to distinguish direct effects from secondary effects arising from loss of 
FMRP. Selective ribosome profiling (SeRP) of an enriched FMRP-containing ribosome 
population can address this issue by identifying direct targets of FMRP-ribosomes that 
are stalled (Figure III.1) (Oh, Becker et al. 2011, Becker, Oh et al. 2013).  FMRP is 
particularly amenable to SeRP based on the current model that 1) FMRP associates with 
polysomes (possibly through a direct interaction), 2) FMRP stalls ribosome movement, 
and 3) FMRP regulates translation and mRNA stability (Darnell, Van Driesche et al. 
2011, Chen, Sharma et al. 2014). Furthermore, FMRP selective ribosome profiling may 
enrich for FMRP targets that are lowly expressed and missed by CLIP studies. Thus, 
selective ribosome profiling may identify the mRNAs bound by FMRP-associated 
ribosomes and could reveal insight into how FMRP-ribosome complexes recognize and 
regulate its targets. 
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Figure III.1: Comparison of conventional and selective ribosome profiling 
Schematic of conventional ribosome profi l ing and selective ribosome profi l ing. Both 
methods use RNase to digest the mRNA to ~30 nucleotide fragments, termed 
ribosome protected fragment (RPF). The RPFs are purif ied either by sucrose 
cushion or gradient for conventional ribosome profi l ing or affinity-purif ication for 
selective ribosome profi l ing. The RPFs are collected for l ibrary preparation, high-
throughput sequencing, and mapping to the transcriptome. 
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Results 
FMRP interacts with ribosomal proteins after RNase digestion  
	Ribosome	profiling	 requires	digestion	of	mRNA	with	RNase,	 leaving	a	~30	
nucleotide	ribosome	protected	 fragmented	(RPF).	Conventional	ribosome	profiling	
captures	all	ribosomes,	whereas	selective	ribosome	profiling	(SeRP)	enriches	 for	a	
ribosome-population	 of	 interest,	 typically	 through	 affinity	 purification.	 Because	
FMRP	 is	 an	 RNA-binding	 protein,	 we	 first	 determined	 whether	 FMRP	 can	 still	
associate	 with	 ribosomes	 after	 RNase	 treatment.	 We	 added	 RNase	 A	 up	 to	 the	
concentration	normally	used	for	ribosome	profiling	experiments,	applied	the	lysate	
to	 a	 sucrose	 cushion,	 and	 observed	 where	 proteins	 found	 after	 centrifugation	
(Figure III.2,	 left).	 Protein	 complexes	 sediment	 primarily	 based	 on	 viscosity,	
molecular	 composition,	 and	 weight;	 ribosomes	 are	 large,	 complex,	 and	 heavy	
structures	 and	 readily	pellet.	Figure III.2	 shows	 that	 ribosomal	proteins	RPS6	and	
RPL4	are	found	in	the	pellet	at	all	RNase	concentrations	as	expected.	FMRP	is	also	
predominantly	 found	 in	 the	 pellet	 whereas	 HuR,	 a	 RBP	 that	 associates	 with	
ribosomes	 in	 a	 RNA-dependent	 manner,	 is	 released	 from	 the	 pellet	 to	 the	
supernatant	 at	 the	 highest	 RNase	 A	 concentration.	 This	 result	 suggests	 that	 after	
digesting	 lysates	 with	 RNase	 A	 at	 a	 concentration	 of	 100ng/A260,	 FMRP	 co-
sediments	 with	 ribosomal	 proteins	 whereas	 the	 RBP	 HuR	 is	 released	 to	 the	
supernatant.		
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Figure III.2: FMRP co-sediments with ribosomal proteins independent of RNA 
Left: Schematic showing RNA-dependent and RNA-independent mechanisms of 
how RNA-binding proteins (RPBs) FMRP and HuR interact with ribosomes. 
FMRP preferentially binds to CDS regions and HuR binds specific motifs in the 3 ′ 
untranslated region (UTR) (Darnell, Van Driesche et al. 2011). RNase is used to 
digest RNA, freeing RBPs that interact with ribosomes in an RNA-dependent 
manner. Applying the lysate through a sucrose cushion allows for proteins to 
sediment based on size, with l ighter complex at the top and heavier complexes 
at the bottom such as ribosomes. After RNAse treatment, RBPs that directly bind 
the ribosomes will remain in the ribosome pellet. Right: Western blot of 
ribosomal proteins, FMRP and HuR from the supernatant and pellet of the 
sucrose cushion with increasing amounts of RNase A. S: supernatant, P: pellet 
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Co-sedimentation	of	factors	does	not	necessarily	reflect	a	direct	interaction;	
consequently,	we	performed	immunoprecipitation	of	HEK	cells	and	cortical	mouse	
tissue	after	RNase	 treatment.	RPL4	 is	a	core	component	of	 the	60S	subunit	 that	 is	
found	 in	 all	 ribosomes.	 Figure III.3	 shows	 that	 immunoprecipitation	 with	 RPL4	
antibody	 co-immunoprecipitates	 (co-IPs)	 ribosomal	 proteins	 RPLP0	 and	 RPS6	 as	
expected,	 because	 they	 are	 all	 constituents	 of	 the	 ribosome.	 Immunoprecipitation	
with	RPL4	antibody	also	co-IPs	FMRP,	 indicating	 that	FMRP	and	 the	ribosome	are	
likely	 part	 of	 the	 same	 complex.	 The	 reverse	 immunoprecipitation	 with	 FMRP	
antibody	 shows	 that	 endogenous	 FMRP	 co-IPs	 RPL4,	 RPLP0,	 and	 RPS6.	 Negative	
controls	HuR	and	FUS	are	RBPs	that	do	not	interact	directly	with	ribosomes	and	are	
not	 co-IP’d	by	 the	RPL4	nor	FMRP	 immunoprecipitation.	The	 IgG	negative	 control	
immunoprecipitation	 pulls	 down	 very	 little	 of	 the	 probed	 proteins.	 Finally,	
immunoprecipitation	 with	 FMRP	 or	 RPL4	 antibodies	 in	 the	 cortex	 yields	 similar	
results	as	HEK	cells	(Figure III.3,	right).	Collectively,	these	results	suggest	that	FMRP	
interacts	with	40S	and	60S	ribosomal	proteins	after	RNase	digestion	of	free	mRNA,	
supporting	the	model	that	FMRP	can	directly	interact	with	the	ribosome.		
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Figure III.3: FMRP interacts with ribosomal proteins independent of RNA 
Western blots demonstrating that FMRP can interact with ribosomal proteins 
independent of RNA in HEK cells ( left) and mouse cortex (right). 
Immunoprecipitation was performed with RPL4, FMRP, or IgG negative control as 
indicated on the top. Proteins probed by western blot are indicated on the left of 
the blots. Negative controls RBP HuR and FUS do not interact with ribosomal 
proteins (RPL4, RPLP0, RPS6) after RNase treatment. TUB: tubulin. 	
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Anti-FMRP enriches for specific RPFs over total ribosomes  
After	 determining	 the	 feasibility	 of	 selective	 ribosome	 profiling	 of	 FMRP-
associated	ribosomes,	RNA	was	extracted	from	the	immunoprecipitation	conditions	
described	 earlier.	 RNA	 from	 the	 following	 IPs	 were	 prepared	 and	 used	 for	 the	
following	comparisons	in	Table III-1.			
	
Table III-1: List of sample types and purpose for FMRP selective ribosome 
profiling 	
Sample	name	 Purpose	
Wild-type FMRP-IP FMRP-enriched ribosome pool 
Wild-type RPL4-IP Total ribosome pool as a reference to calculate FMRP-ribosome enrichment 
Wild-type IgG-IP Negative control to establish background, nonspecific binding to beads 
Fmr1-/y FMRP-IP Negative control to establish FMRP antibody specificity 
Fmr1-/y RPL4-IP Identifies changes in ribosome occupancy between wild-type and Fmr1-/y enriched mRNAs 
	
Figure III.4	 shows	 that	 the	 majority	 of	 reads	 from	 selective	 ribosome	
profiling	 mapped	 to	 protein-coding	 regions,	 as	 expected	 for	 ribosome	 profiling	
libraries.	 Roughly	 20%	 of	 reads	 mapped	 to	 the	 5′	 and	 3′UTR,	 comparable	 to	
conventional	ribosome	profiling	libraries.	Figure III.5	shows	a	volcano	plot	with	125	
mRNAs	 that	 are	 enriched	 in	 FMRP/co-IP’d	 ribosomes	 over	 total	 L4/co-IP’d	
ribosomes	and	IgG	negative	control	(log2FC	>	0.75,	padj	<	0.01)	(see	Table III-2	for	
full	 list).	 The	 mRNAs	 enriched	 by	 anti-FMRP	 ribosomes	 overlapped	 significantly	
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with	FMRP	targets	identified	by	CLIP	experiments	in	the	cortex	(25/125)	and	SFARI	
autism	genes	 (23/125).	However,	many	mRNAs	did	not	overlap	with	direct	FMRP	
binding	targets,	suggestive	of	a	novel	mode	of	regulation	by	FMRP.		
	 	
 
Figure III.4: Gene body mapping frequency for conventional and selective 
ribosome profiling   
Percentage of uniquely mapped reads to gene regions from conventional and 
selective ribosome profi l ing from RPL4-IP and FMRP-IP from the cortex. Blue = 
CDS, red = 5 ′ and 3 ′ untranslated regions (UTRs), green = introns, purple = 
intergenic. 	
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Figure III.5: Anti-FMRP enriches for specific mRNAs 
Volcano plot of RPFs that are enriched in anti-FMRP ribosomes over total 
r ibosomes and IgG negative control (x-axis: log2 fold enrichment, y-axis: p-
adjusted value with BH correction). 125 mRNAs pass a statistical cutoff of padj < 
0.01 and log2FC > 0.75. Venn diagram showing gene overlap of the 125 mRNAs 
enriched in anti-FMRP ribosomes compared to FMRP targets identif ied by CLIP in 
the mouse cortex (Darnell, Van Driesche et al. 2011) and SFARI autism genes 
(gene.sfari.org).  
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	Figure III.6	 shows	 examples	 of	 mRNAs	 enriched	 in	 anti-FMRP-associated	
ribosomes.	 Nuclear	 receptor	 corepressor	 1	 (Ncor1) and E1A binding protein p300 
(Ep300) are consistent FMRP targets identified from 3 CLIP studies and	show	an	even	
distribution	 of	 anti-FMRP	 ribosome	 densities	 along	 the	 CDS	 (Figure III.6,	 left)	
(Darnell,	Van	Driesche	et	al.	2011,	Ascano,	Mukherjee	et	al.	2012,	Maurin,	Lebrigand	
et	 al.	 2018).	 Both	have recently been implicated in epigenetic alterations in mice that 
contribute to FXS phenotypes (Darnell, Van Driesche et al. 2011, Ascano, Mukherjee et 
al. 2012, Korb, Herre et al. 2017, Li, Stockton et al. 2018, Maurin, Lebrigand et al. 2018). 
For	some	mRNAs,	anti-FMRP	ribosomes	have	a	unique	binding	pattern	compared	to	
total	ribosomes.	For	example,	lysine	demethylase	5C		(Kdm5c	)	and	forkhead	box	P1	
(Foxp1)	have	 enrichment	 of	 anti-FMRP	 ribosomes	 in	 the	3′	 end	of	 the	CDS,	which	
may	be	suggestive	of	stalled	ribosomes	or	recognition	of	a	specific	section	of	mRNA	
(Figure III.6,	right).	Both	Kdm5c	and	Foxp1	are	high	confidence	SFARI	autism	genes	
with	mutations	 identified	 in	 humans	with	 intellectual	 disability	 (gene.sfari.org).	 In	
summary,	FMRP	1)	co-IPs	ribosome	complexes	and	 identifies	specific	RPFs,	2)	are	
enriched	over	total	ribosomes	and	IgG	negative	control,	and	3)	have	unique	binding	
preference	on	CDS.		
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Figure III.6:  Different modes of binding by anti-FMRP ribosomes 
Read density plots for mRNAs enriched by anti-FMRP ribosomes. Normalized reads 
are plotted along the CDS position in nucleotides. Solid red l ine = WT FMRP-IP, 
dashed red l ine =  Fmr1-/y FMRP-IP, solid blue l ine = WT RPL4-IP, and dashed blue 
l ine =  Fmr1-/y RPL4-IP. 	 	
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Anti-FMRP enriches for specific RPFs independent of FMRP   
When	we	compared	the	FMRP	coIP-enriched	mRNAs	between	wild-type	and	
Fmr1-/y	 mice,	 we	 were	 surprised	 to	 see	 very	 few	 differences	 between	 the	 two	
samples	 (Figure III.7A).	 The	 few	 mRNAs	 that	 were	 differentially	 enriched	 in	 the	
FMRP	 co-IP’d	 ribosomes	 had	 differences	 in	 total	 RPFs	 (e.g.	 Fmr1)	 that	 reflect	
differences	in	either	total	RNA	or	translation.	Given	that	the	reads	enriched	by	anti-
FMRP	likely	reflect	real	ribosome	fragments,	there	could	be	3	possibilities	to	explain	
these	 results.	 Figure III.7B	 depicts	 a	 model	 where	 anti-FMRP	 could	 recognize	 i)	
another	 ribosome-associated	 protein,	 ii)	 the	 growing	 nascent	 peptide	 on	 the	
ribosome,	 or	 iii)	 a	 co-translational	 interactor	 that	 binds	 the	 growing	 nascent	
peptide.	For	the	first	possibility,	the	most	logical	candidates	would	be	the	autosomal	
paralogues,	 fragile	X	related	proteins	1	and	2	(FXR1/2P).	 In	mammals,	FXR2P	and	
FXR1P	share	a	high	level	of	homology	with	FMRP.	FXR2P	and	FXR1P	are	also	found	
in	polyribosomes,	and	the	FMRP	region	required	for	binding	to	the	60S	(exon	13	and	
14)	 is	 conserved	with	 dFMRP	 and	 FXR2P	 (Siomi,	 Zhang	 et	 al.	 1996,	 Darnell,	 Van	
Driesche	 et	 al.	 2011).	 In	 drosophila,	 there	 is	 one	 FMRP	 that	 is	 structurally	 more	
similar	 to	 the	 FXRs	 than	 to	 mammalian	 FMRP	 (Figure III.7C).	 Mammalian	 FMRP	
contains	a	unique	expansion	of	exon	11	and	12	and	a	shorter	C-terminus	compared	
to	dFMRP	and	FXR2P.		
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Figure III.7: Anti-FMRP enriches for specific mRNAs independent of FMRP 
A) Scatter plot of counts from FMRP-IP of wild-type and Fmr1-/y cortices shows very 
few mRNAs differentially enriched based on genotype. mRNAs that are 
differentially enriched in the FMRP-IP are from changes in total r ibosomes (e.g. 
Fmr1). B) A model of how anti-FMRP may enrich for specific RPFs via recognition 
of i) another ribosome-associated protein (e.g. paralogue FXR2P), i i) the nascent 
peptide of the translated mRNA, or i i i) through a co-translational interactor. C) The 
Fragile X related family of proteins have conserved protein domains.  The agenet-
l ike domains are required for protein-protein interactions, such as with FXR1P/2P, 
CYFIP1/2 and NUFIP. The K Homology (KH) domains and arginine-glycine-rich 
(RGG) box mediate the RNA binding function of FMRP. The KH domains are 
required for FMRP association with polyribosomes. The RGG box mediates FMRP 
binding to G-quadruplex containing mRNAs.  The asterisk and red box corresponds 
to the region required for 60S binding. The solid l ine indicates the FMRP-specific 
expansion in exon 11 and 12.  
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We	 observed	 that	 Fmr1	and	 Fxr2	 mRNAs	were	 enriched	 in	 the	 anti-FMRP	
ribosome	list	from	Figure III.5/Table III-2	and	proposed	that	anti-FMRP	recognized	
the	 growing	 nascent	 peptide	 from	 Fmr1	 and	 Fxr2	 translation.	 Normalized	 read	
density	 plots	 for	Fmr1	 and	 Fxr2	are	 indicated	 in	Figure III.8A.	 For	 Fxr2,	 the	 peak	
enrichment	 of	 anti-FMRP	 ribosomes	 correlate	 with	 the	 emergence	 of	 the	 FMRP	
antibody	 epitope	 (amino	 acids	 550-end	 of	 human	 FMRP	 based	 on	 the	
manufacturer’s	 datasheet)	 from	 the	 ribosome,	 suggesting	 that	 anti-FMRP	 was	
enriching	 for	Fxr2	 footprints	by	cross	reacting	 to	 the	epitope	of	 the	nascent	chain.	
Interestingly,	 Fmr1	 has	 a	 different	 binding	 pattern	 from	 Fxr2,	 where	 the	 peak	
enrichment	of	anti-FMRP	ribosome	footprints	occurs	before	the	epitope	region.	This	
suggests	 that	 anti-FMRP	 binds	 predominantly	 full-length	 FMRP,	 and	 FMRP-
associated	 ribosomes	 may	 specifically	 recognize	 Fmr1	 directly	 or	 via	 a	 co-
translational	 interactor	 (Figure III.7B,	model	 I	 and	 III).	 Immunoprecipitation	using	
anti-FMRP	 in	 wild-type	 and	 Fmr1-KO	 cortex	 reveals	 that	 anti-FMRP	 pulls	 down	
FXR2P	in	Fmr1-/y	animals,	confirming	that	the	antibody	cross-reacts	and	pulls	down	
FXR2P	 (Figure III.8B).	 Functionally,	 binding	 targets	 of	 FXR2P	 and	 FXR1P	 overlap	
95%	with	 FMRP	 targets	 identified	 by	 CLIP	 in	HEK	 cells	 (Ascano,	Mukherjee	 et	 al.	
2012).	The	mRNAs	enriched	in	anti-FMRP	overlap	significantly	with	FXR2P	binding	
targets	 in	 HEK	 cells	 (Figure III.8C).	 Collectively,	 these	 results	 suggest	 that	 some	
mRNAs	enriched	by	anti-FMRP	may	occur	by	cross-reactivity	to	the	FXR2P.		
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Figure III.8: Anti-FMRP cross-reacts to paralogue FXR2P 
A) Read density plots for Fxr2  (top) and Fmr1  (bottom). Normalized reads are 
plotted along the CDS position in nucleotides. Solid red l ine = WT FMRP-IP, 
dashed red l ine = Fmr1-/y FMRP-IP, solid blue l ine = WT RPL4-IP, and dashed blue 
l ine = Fmr1-/y RPL4-IP. The gray box corresponds to the FMRP antibody epitope. B) 
Western blot showing that immunoprecipitation with FMRP antibody pulls down 
FXR2P in wild-type and Fmr1-/y cortex. C) Overlap of anti-FMRP ribosome enriched 
mRNAs and FXR2P CLIP targets from HEK cells (Ascano, Mukherjee et al. 2012). 
P-value from Fisher exact t-test and the genes past f i l tering from differential 
expression analysis were used as the background size. 
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SeRP in FMRP-FLAG neural progenitor cells 
We	propose	 to	 circumvent	 anti-FMRP	 cross-reactivity	 to	 FXR2P	 by	 using	 a	
FMRP-FLAG	 human	 progenitor	 stem	 cell	 line	 (hPSC)	 (Li,	 Shin	 et	 al.	 2020).	 Using	
CRISPR-Cas9,	a	3XFLAG	tag	was	 integrated	 into	 the	C-terminus	of	FMRP	 in	a	male	
hPSC	line.	First,	we	determined	if	FMRP-FLAG	interacts	with	polysomes	in	a	similar	
manner	as	wild-type	FMRP.	We	prepared	lysate	from	the	FMRP-FLAG	and	parental	
hPSC	lines	and	applied	the	lysate	to	a	linear	sucrose	gradient	for	polysome	analysis.	
Figure III.9	 shows	 that	 the	 polysome	 profile	 is	 similar	 between	 FMRP-FLAG	 and	
wild-type	FMRP,	indicating	a	lack	of	global	changes	in	translation	in	the	FMRP-FLAG	
hPSCs.	We	 then	extracted	protein	 from	each	sucrose	gradient	 fraction	 for	western	
blot	 analysis	 and	 probed	 for	 RPS6,	 FMRP	 or	 FLAG.	 The	 association	 of	 wild-type	
FMRP	and	FMRP-FLAG	with	polyribosomes	are	also	similar,	and	the	amount	of	RPS6	
is	also	similar	between	the	two	cell	lines	(Figure III.9,	bottom).	Taken	together,	the	
polysome	 gradient	 analysis	 indicates	 that	 FMRP-FLAG	 fusion	 protein	 behaves	
similar	to	wild-type	FMRP.	The	FMRP	selective	ribosome	profiling	experiment	will	
be	repeated	in	hPSCs	with	FMRP-FLAG.	A	FLAG	antibody	will	be	used	to	enrich	for	
FMRP-FLAG	associated	ribosomes,	and	the	wild-type	parental	cells	will	serve	as	the	
negative	 control	 instead	 of	 IgG.	 This	 experimental	 design	will	 allow	us	 to	 identify	
mRNAs	enriched	by	FMRP-associated	ribosomes	independent	of	the	paralogues.	
We	observed	enrichment	of	specific	mRNAs	by	FMRP-associated	ribosomes	
in	 wild-type	 mice	 and	 mice	 lacking	 FMRP,	 which	 may	 be	 explained	 by	 FMRP	
antibody	 cross-reactivity	 to	 FXR2P.	 Another	 possibility	 is	 that	 FMRP-associated	
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ribosomes	recognize	highly	 localized	and	unique	binding	 to	CDS	 that	 is	missed	by	
our	whole	gene	analysis.	Because	we	cannot	perform	reliable	peak	detection	with	
only	one	FMRP	SeRP	library	from	Fmr1-/y	mice,	we	will	perform	this	analysis	in	the	
FMRP-FLAG	libraries	which	will	have	replicates.		
	
	 	
 
Figure III.9: FMRP-FLAG cosediments with polysomes similar to wild-type FMRP 
Polysome gradient analysis of wild-type FMRP (left) and FMRP-FLAG (right) hESCs 
with continuous absorbance at 254nm. Sedimentation is left to right in a continuous 
10-50% (w/v) sucrose gradient. Global translation status is similar between wild-
type and FMRP-FLAG hESCs. Bottom: western blots are shown for RPS6, FMRP, 
and FLAG from all fractions of the gradient. FMRP-FLAG cosediments with 
polyribosomes similar to wild-type FMRP.  
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Technical challenges to overcome for FMRP SeRP  
A	 common	 challenge	 in	 selective	 ribosome	 profiling	 experiments	 is	
minimizing	post-lysis	 interactions	and	stabilizing	the	desired	ribosome-complex	of	
interest.	When	we	run	a	sucrose	gradient	to	observe	FMRP	co-sedimentation	after	
RNase	 digestion,	 we	 observe	 that	 most	 of	 the	 FMRP-polyribosome	 interaction	
depends	 on	 RNA,	 consistent	 with	 others	 publications	 (Figure III.10,	 top	 left	 and	
right)	 (Stefani,	 Fraser	 et	 al.	 2004,	 Rachid	 El	 Fatimy	 2016).	 Polysome	 gradient	
analysis	 reveals	 that	 a	 substantial	 population	 of	 FMRP	moves	 to	 the	 free	 fraction	
after	 RNase	 digestion	 of	 mRNA,	 and	 there	 is	 no	 enrichment	 of	 FMRP	 in	 the	
monosome	fraction,	where	the	~30nt	RPFs	are	expected	to	cosediment.	This	result	
suggests	that	either	a	small	percentage	of	the	FMRP	population	is	directly	associated	
with	 ribosomes	 or	 that	 the	 FMRP-ribosome	 interaction	 is	 transient	 and/or	
stabilized	by	RNA.	To	address	the	latter	concern,	in	vivo	cross-linkers	are	frequently	
used	 in	 selective	 ribosome	 profiling	 experiments	 to	 stabilize	 ribosome-complex	
interactions.	 We	 treated	 HEK	 cells	 briefly	 with	 dithiobis	 succinimidyl	 propionate	
(DPS),	 a	 cell-membrane	 permeable	 lysine-lysine	 cross-linker.	 In	 vivo	 cross-linking	
with	DSP	reveals	mild	stabilization	of	the	FMRP-ribosome	interaction;	after	RNaseI	
digestion,	 slightly	 more	 FMRP	 cosediments	 with	 the	 monosome	 fraction	 in	 DSP	
cross-linked	samples	compared	to	non-cross-linked	samples	when	compared	to	the	
amount	of	monosome	and	RPS6	in	the	fractions	(Figure III.10).	However,	even	with	
DSP	 crosslinking,	 most	 of	 FMRP	 still	 moves	 to	 the	 free	 fraction	 after	 RNase	
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digestion.	 Thus,	 an	 additional	 agent	 to	 stabilize	 protein-RNA	 interactions	may	 be	
required,	such	as	formaldehyde.		 	
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Figure III.10: Crosslinking stabilizes some FMRP-ribosome interaction  
Polysome gradient analysis of HEK cells with continuous absorbance at 254nm. 
Sedimentation is left to right in a 10-50% (w/v) sucrose gradient. Top panel: 
noncross-linked HEK cells (-XL) with and without RNaseI digestion. Bottom panel: 
HEK cells treated with the in vivo crosslinking agent DSP (+XL) with and without 
RNase I digestion. Western blots of fractions from the entire gradient are shown for 
FMRP and RPS6. RNase I treatment collapses polysomes into monosomes, 
indicated with black square. DSP stabil izes some FMRP-ribosome interaction. XL = 
cross-linked.   
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Discussion 
Overlapping function of FXRs and FMRP  
FMRP,	FXR1P,	and	FXR2P	make	up	the	Fragile-X	related	family	of	proteins	in	
mammals.	FMR1	 is	 the	only	member	of	 the	 family	 that	when	 inactivated,	 causes	a	
human	disease;	as	a	consequence,	FXR1/2	are	relatively	poorly	studied.	Because	the	
brain	 targets	 of	 FXR1/2P	 are	 unknown,	 the	 targets	 specific	 to	 FMRP	 are	 also	
unknown.	The	FMRP	family	of	related	proteins	is	well	conserved	through	the	RNA-
binding	KH	domains	and	60S	 interaction	 region	 (Figure III.7),	 and	 thus	 the	mRNA	
targets	 that	 depend	 on	 these	 regions	 should	 also	 largely	 overlap.	 In	 HEK	 cells,	
targets	of	ectopically	expressed	FXR1P	and	FXR2P	overlap	95%	with	FMRP	targets	
and	are	enriched	for	the	same	RNA	recognition	elements	(Ascano,	Mukherjee	et	al.	
2012).	Our	FMRP	selective	ribosome	profiling	results	also	suggests	that	the	targets	
enriched	 by	 FXR-associated	 ribosomes	 are	 the	 same,	 though	 to	 validate	 this	 we	
would	need	to	perform	FXR2P	selective	ribosome	profiling.		
Work	from	mice	lacking	Fxr2	support	some	overlapping	functions	with	Fmr1;	
a	 combined	 Fxr2/Fmr1-KO	 mouse	 has	 a	 more	 severe	 phenotype	 than	 each	
individual	KO	mouse	alone	(Bontekoe,	McIlwain	et	al.	2002,	Spencer,	Serysheva	et	
al.	 2006,	 Saré,	 Figueroa	 et	 al.	 2019).	 In	 addition,	 synaptic	 localization	of	 FXR2P	 is	
disrupted	 in	 Fmr1	 knockout	 mice	 (Wang,	 Smith	 et	 al.	 2016)	 but	 not	 FXR1P,	
indicating	that	FXR2P	contributes	to	the	synaptic	dysfunction	of	FXS	mice.	Fxr2-KO	
mouse	models	also	suggests	 that	FXR2P	 is	required	 for	proper	brain	development	
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and	function,	as	FXR2P	deficiency	impairs	neurogenesis	in	the	dentate	gyrus	of	the	
hippocampus	by	reducing	Noggin	mRNA	stability	(Guo,	Zhang	et	al.	2011).		
Why	are	mutations	in	FMR1	associated	with	a	human	disease	and	not	FXR1/2	
if	the	FXR	family	is	well	conserved?	FXS	is	caused	by	an	unstable	GCC	trinucleotide	
repeat	 expansion	 in	 the	 5′UTR	of	FMR1	 and	 this	 repeat	 is	 not	 present	 in	FXR1	 or	
FXR2,	 indicative	of	difference	 in	disease	mechanism	(Verkerk,	Pieretti	et	al.	1991).	
Also,	although	FXR1P	and	FXR2P	have	some	overlapping	function	with	FMRP	based	
on	work	in	mouse	models,	the	paralogues	do	not	completely	compensate	for	loss	of	
FMRP	(Spencer,	Serysheva	et	al.	2006,	Saré,	Figueroa	et	al.	2019).	This	 indicates	a	
unique	function	of	FMRP.	The	RGG	box	and	C-terminus	of	FMRP	are	more	divergent	
from	the	paralogues	(Figure III.7),	leading	to	the	speculation	that	these	regions	are	
important	for	FMRP-specific	functions	over	the	paralogues.	One	possibility	could	be	
that	 the	 FXRs	 bind	 similar	 mRNAs	 but	 have	 different	 functional	 outcomes	 and	
regulation.	 Additional	 unbiased	 transciptome	methods	 such	 as	 CLIP	 of	 FXR1P/2P	
and	RNA-seq	of	mouse	models	are	needed	to	distinguish	the	unique	and	overlapping	
functions	of	the	paralogues	from	FMRP.		
Auto-regulation of Fmr1 translation by FMRP 
Our	FMRP	selective	ribosome	profiling	reveals	that	FMRP	enriches	for	RPFs	
from	 its	 own	mRNA,	 suggesting	 that	 FMRP	 regulates	 it’s	 own	mRNA	 through	 the	
ribosome.	 FMRP	 binds	with	 high	 affinity	 to	 its	 own	mRNA,	which	 is	mediated	 by	
FMRP	 directly	 binding	 to	 the	 RGG-coding	 region	 of	 FMR1	 to	 repress	 protein	
synthesis	(Ashley,	Wilkinson	et	al.	1993,	Schaeffer,	Bardoni	et	al.	2001).	Our	FMRP	
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selective	ribosome	profiling	indicates	that	the	peak	enrichment	of	Fmr1	RPFs	occurs	
before	the	RGG-coding	region,	suggestive	of	distinct	RNA-dependent	and	ribosome-
dependent	 functions	of	FMRP	 in	regulating	Fmr1.	Collectively,	 these	data	supports	
the	model	proposed	by	Chen	et	al	of	how	FMRP	may	simultaneously	bind	mRNA	and	
the	 ribosome:	 FMRP	 binds	 to	 G-quadruplex	 containing	 mRNAs,	 such	 as	 the	 RGG	
region	 of	 Fmr1,	 and	 then	 docks	 on	 the	 ribosome	 to	 repress	 translation	 (Chen,	
Sharma	et	 al.	 2014).	The	outcome	of	FMRP	binding	 to	 ribosomes	on	 its	on	mRNA	
may	be	translational	repression	and/or	mRNA	decay.		
FMRP-ribosome interaction 
	 We	 initiated	 this	 project	 based	 on	 the	 model	 that	 FMRP	 may	 be	 directly	
associated	with	the	ribosome	as	proposed	by	Chen	et	al	(Chen,	Sharma	et	al.	2014).	
Our	 initial	 results	 supported	 this	 model	 based	 on	 the	 observation	 that	 FMRP	
sediments	 with	 the	 ribosomal	 protein	 pellet	 and	 FMRP	 co-IPs	 with	 ribosomal	
proteins	after	RNAse	digestion.	Sucrose	gradient	analysis,	which	is	higher	resolution	
than	 a	 sucrose	 cushion,	 reveals	 that	 most	 of	 the	 FMRP-polysome	 interaction	 is	
dependent	on	RNA,	which	is	consistent	with	data	from	others	(Stefani,	Fraser	et	al.	
2004,	 Rachid	 El	 Fatimy	 2016).	 Differences	 in	 the	 sucrose	 cushion	 and	 gradient	
results	can	arise	from	the	different	populations	of	FMRP	captured	by	both	methods.	
A	sucrose	cushion	will	capture	all	proteins,	whereas	a	sucrose	gradient	misses	the	
heavier	 sedimenting	 ribosomes	 of	 long	mRNAs	 at	 the	 bottom	 of	 the	 tube,	 where	
FMRP	is	enriched	in.	Regardless,	our	results	suggest	that	the	RPFs	captured	by	our	
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FMRP-IP	selective	ribosome	profiling	represent	a	small	population	of	direct	FMRP-
ribosome	complexes.		
Our	results	suggest	that	that	a	small	population	of	FMRP	may	bind	directly	to	
the	 ribosome	 and/or	 the	 FMRP-ribosome	 interaction	 may	 be	 transient	 and	
stabilized	by	RNA	 (rRNA	and/or	mRNA).	The	 latter	 interpretation	 is	 at	 odds	with	
the	reported	high	affinity	(KD	~	20nM)	that	dFMRP	binds	to	ribosomes	from	Chen	et	
al	(Chen,	Sharma	et	al.	2014).	Because	multiple	studies	find	that	FMRP	can	interact	
directly	with	 select	 ribosomal	 proteins	 and	 ribosomal	RNA,	 one	possibility	 is	 that	
FMRP	may	directly	bind	to	ribosomes	via	rRNA,	and	RNase	digestion	disrupts	 this	
interaction	(Ishizuka,	Siomi	et	al.	2002).	However,	 it	 is	unclear	 if	FMRP	binding	 to	
rRNA	occurs	in	a	specific	manner.	Based	on	the	model	by	Chen	et	al	that	FMRP	binds	
the	intersubunit	space	of	the	ribosome,	FMRP	may	be	in	close	enough	proximity	to	
cross-link	 to	 tRNAs.	 Photoactivatable	 Ribonucleoside-Enhanced	 Crosslinking	 and	
Immunoprecipitation	 (PAR-CLIP)	 is	 a	 method	 that	 reveals	 high	 resolution	 RBP	
binding	 based	 on	 T	 to	 C	 conversions	 in	 cDNA	 (Hafner,	 Landthaler	 et	 al.	 2010).		
Reanalysis	of	FMRP	PAR-CLIP	datasets	may	reveal	if	FMRP	binds	rRNA	and	tRNA	in	
a	 specific	manner	 and	 provide	 support	 if	 FMRP	 directly	 interacts	with	 ribosomes	
(Ascano,	 Mukherjee	 et	 al.	 2012).	 For	 example,	 the	 RBP	 Zinc	 Finger	 Protein	 598	
(ZNF598)	is	a	ribosome-associated	protein	that	participates	in	ribosome-associated	
quality	 control,	 a	 pathway	 to	 disassemble	 ribosomes	 after	 translation	 of	 poly(A)	
residues.	ZNF598	shares	a	similar	binding	pattern	as	FMRP,	where	most	CLIP	sites	
occur	in	the	CDS	(Garzia,	Jafarnejad	et	al.	2017).	PAR-CLIP	experiments	reveals	that	
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ZNF598	 binds	 to	 specific	 sites	 on	 5S	 rRNA	 and	 is	 enriched	 for	 binding	 to	
tRNALys(UUU),	 consistent	 with	 a	 role	 of	 ZNF598	 in	 sensing	 AAA	 codons	 on	
ribosomes.		 	
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Materials and methods 
Sucrose	cushion		
Roughly	9	million	HEK	cells	were	lysed	in	1mL	of	polysome	lysis	buffer	(20mM	Tris-
HCl	pH	7.4,	100mM	KCl,	5mM	MgCl2	100ug/mL	cycloheximide,	1mM	DTT,	1X	EDTA-
free	 protease	 inhibitory,	 and	 0.3%	 Triton-X100)	 in	 a	 Dounce	 homogenizer.	 The	
A260	was	measured,	 and	 the	 lysate	was	 treated	with	 1ng,	 10ng,	 or	 100ng	RNase	
A/A260	for	30min	at	25C	with	300rpm	rotation.	The	lysate	was	then	layered	onto	a	
sucrose	cushion	(0.5M	and	1M	of	sucrose	dissolved	in	polysome	lysis	buffer	without	
Triton-X100)	and	centrifuged	at	80,000	for	3hr	at	4C	in	a	TL1-100.3.	The	pellet	was	
dissolved	in	equal	volume	as	the	supernatant	fraction	in	a	TBS	solution	with	1%	SDS	
pre-warmed	 to	 95C.	 The	 pellet	 was	 incubated	 for	 5min	 and	 mixed	 to	 ensure	
resuspension	of	the	pellet.		
	
In	vivo	DSP	cross	linking		
On	the	day	before	cell	 lysis,	HEK	cells	were	split	 into	a	150mm	dish	to	reach	80%	
confluency	on	 the	day	of	experiment.	The	media	was	aspirated	and	 the	cells	were	
washed	2X	with	15mL	of	warmed	PBS	containing	100ug/mL	of	cycloheximide.	The	
media	 was	 removed	 thoroughly	 to	 avoid	 crosslinking	 of	 free	 amino	 acids	 in	 the	
media.	 Cells	 were	 crosslinked	 with	 15mL	 of	 1mM	 DSP	 dissolved	 in	 PBS	 at	 room	
temperature	for	1min	with	gentle	rocking.	The	DSP	solution	was	removed,	and	the	
crosslinking	 reaction	 was	 quenched	 with	 15mL	 of	 50mM	 Tris,	 pH	 7.4	 at	 room	
temperature	for	1min	with	gentle	rocking.	The	Tris	solution	was	removed,	and	the	
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cells	 were	 washed	 2X	 with	 15mL	 of	 ice-cold	 PBS	 containing	 100ug/mL	 of	
cycloheximide.	 Cells	 were	 lysed	 directly	 with	 500uL	 of	 ice-cold	 polysome	 buffer	
(20mM	 Tris-HCl	 pH	 7.5,	 5mM	MgCl2,	 100mM	 KCl,	 1mM	DTT,	 100ug/mL	 CHX,	 1X	
EDTA-free	 protease	 inhibitor,	 1%	 NP-40)	 added	 to	 the	 plate.	 Cells	 were	 scraped	
from	the	plate	and	transferred	to	a	1.5mL	tube.	The	cells	were	triturated	through	a	
25G	needle	10X	 in	 the	 cold	 room	and	 incubated	on	 ice	 for	10min.	The	 lysate	was	
spun	 at	 14,000g	 for	 10min	 at	 4C.	 The	 supernatant	 was	 collected	 and	 the	 RNA	
concentration	measured	by	Nanodrop	 and	Qubit	RNA	Broad	Range	 assay.	 For	 the	
RnaseI	digested	samples,	RNaseI	was	added	at	100U/120ug	of	RNA	for	5min	at	4C	
with	 end-over-end	 rotation.	 SuperRnaseIn	 (2.5uL)	 was	 added	 to	 stop	 the	 RNase	
digestion.	The	lysate	was	layered	onto	a	sucrose	gradient	was	described	below.		
	
hPSC	cell	lysis	and	polysome	profiling	analysis		
Frozen	hPSCs	cell	pellets	were	thawed	in	polysome	buffer	(20mM	Tris-HCl,	pH	7.4,	
5mM	 MgCl2,	 100mM	 KCl,	 1mM	 DTT,	 100ug/mL	 cycloheximide,	 1X	 EDTA-free	
protease	inhibitor	(Sigma,	#11836170001),	and	1%	TritonX-100	w/v)	for	5min	on	
ice	 and	 the	 resuspended.	 A	 25G	 needle	 was	 used	 to	 triturate	 the	 cells	 10X	 and	
incubated	on	ice	for	10min.	The	homogenate	was	centrifuged	at	14,000g	for	10min	
at	 4°C.	 The	 supernatant	 was	 collected	 and	 the	 lysate	 was	 quantified	 using	 a	
Nanodrop.	 The	 samples	 were	 adjusted	 to	 equal	 concentrations	 of	 RNA	 using	
polysome	 buffer	 and	 equal	 amounts	 of	 lysate	 was	 layered	 over	 a	 10-50%	 w/v	
sucrose	 gradient	 prepared	 in	 polysome	 buffer	with	 100ug/mL	 cycloheximide	 and	
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centrifuged	at	35K	rpm	for	2.5hr	at	4°C	using	a	SW41	rotor.	The	sucrose	gradients	
were	 then	 fractionated	 from	 top	 to	 bottom	 and	 monitored	 with	 continuous	 UV	
absorbance	(A254).	For	downstream	western	blots,	equal	amounts	were	taken	from	
each	fraction.		
	
Western	blot	analysis	
4X	Laemelli	buffer	(8%	sodium	dodecyl	sulfate,	20%	glycerol,	0.008%	bromophenol	
blue,	250mM	Tris-HCl	pH	6.8,	800mM	dithiothreitol)	was	added	to	samples	to	reach	
a	1X	concentration	and	heated	at	95°C	for	10min.	Samples	were	loaded	onto	a	10%	
SDS-PAGE	 gel	 and	 ran	 at	 80V	 until	 samples	 reached	 the	 end	 of	 the	 stacking	 gel,	
which	was	 then	run	at	120V.	The	proteins	were	 transferred	 to	a	PVDF	membrane	
for	2	hours	at	100V	in	the	cold	room.	The	membranes	were	blocked	in	5%	milk	in	
TBS-T	 for	 1	 hour	 at	 room	 temperature	 and	 incubated	 with	 primary	 antibody	 in	
blocking	buffer	overnight	at	4°C.	The	blots	were	washed	4X	for	5	minutes	each	with	
TBS-T	and	incubated	with	HPR	conjugated	secondary	antibody	in	5%	milk	in	TBS-T	
for	 1	 hour	 at	 room	 temperature.	 For	 immunobloting	 of	 IP	 experiments,	 TrueBlot	
rabbit	 secondary	 HPR-conjugated	 antibody	 was	 used	 (Rockland,	 #18-8816-33).	
Blots	 were	 washed	 4X	 for	 5	 minutes	 each	 before	 development	 with	 ECL.	 The	
following	primary	antibodies	were	used	for	the	study:	 	FMRP	(Abcam,	#ab17722),	
FXR2	(BD	Biosciences,	#611330),	RPS6	(Cell	Signaling,	#2217S),	RPL4	(Proteintech,	
#11302-1-AP),	FLAG	M2	antibody	(Sigma,	#F1804).		
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RPL4	and	FMRP	immunoprecipitation	
Male	 wild-type	 C57BL/6	 mice	 and	 Fmr1tmCgr	 mice	 (Jackson	 Laboratory,	 stock	
number	 003025)	 were	 used	 (P22-23).	 Brains	 were	 rapidly	 removed	 and	 quickly	
washed	 in	 ice-cold	 1X	 Hank’s	 Buffered	 Saline	 Solution	 with	 100ug/mL	
cycloheximide.	 The	 mid-brain,	 corpus	 callosum,	 and	 hippocampi	 were	 dissected	
from	 the	 cortices.	 Two	 hemispheres	 of	 the	 cortices	 were	 added	 to	 a	 Dounce	
homogenizer	 with	 1mL	 of	 polysome	 lysis	 buffer	 (20mM	 Tris-HCl,	 100mM	 KCl,	
10mM	MgCl2,	1mM	DTT,	100ug/mL	CHX,	and	1X	EDTA-free	protease	inhibitor).	The	
cortices	were	lysed	with	8	strokes	each	of	A	(loose)	and	B	(tight)	pestles.	The	lysate	
was	transferred	to	a	1.5mL	tube	and	NP-40	added	to	a	final	1%	v/v.	The	lysate	was	
incubated	on	ice	for	10min,	centrifuged	at	2,000g	for	10min	at	4C.	The	supernatant	
was	collected	and	spun	at	16,000g	for	10min	at	4C.	The	supernatant	was	collected	
and	the	A260	measured	on	the	Nanodrop.	For	the	wild-type	and	Fmr1-KO	samples,	
the	 lysate	 concentration	 was	 adjusted	 to	 be	 equal.	 The	 lysate	 was	 digested	 with	
100ng	/A260	of	RNase	A	for	30min	at	25C	with	end-over-end	rotation.	After	RNase	
reaction,	SuperRNasIn	was	added.	The	lysate	was	centrifuged	at	10,000g	for	5min	at	
4C,	 and	 the	 supernatant	 was	 collected	 for	 IP.	 Roughly	 1.3mL	 of	 lysate	 was	
precleared	for	30min	at	4C	with	washed	Protein	A	Dynabeads	resuspended	in	lysis	
buffer.	The	 lysate	was	then	equally	split	 for	the	RPL4,	FMRP,	or	IgG	IP,	and	5ug	of	
antibody	was	 added	directly	 to	 the	 lysate,	 corresponding	 to	 roughly	5	A260	units	
per	 IP.	 The	 antibody	 and	 lysate	 was	 incubated	 for	 3hr	 at	 4C	 with	 end-over-end	
rotation.	50uL	of	washed	Protein	A	Dynabeads	were	 then	added	 to	 the	 lysate	and	
	
 
111	
111 
incubated	for	1hr	at	4C	with	end-over-end	rotation.	The	unbound	supernatant	was	
removed,	and	 the	beads	were	washed	with	1mL	of	 cold	polysome	buffer	 for	5min	
with	end-over-end	rotation	for	a	total	of	4	times.	The	last	wash	was	transferred	to	a	
new	 tube	 to	 avoid	 eluting	 nonspecifically	 bound	 proteins	 and	 mRNAs.	 RNA	 was	
eluted	 with	 1mL	 of	 Trizol	 and	 protein	 was	 eluted	 with	 1X	 Laemmeli	 buffer	 (2%	
sodium	dodecyl	sulfate,	10%	glycerol,	0.002%	bromophenol	blue,	62.5mM	Tris-HCl	
pH	6.8,	200mM	dithiothreitol)	and	heated	for	10	minutes	at	95C.		
	
Ribosome	profiling	library	prep	and	sequencing	analysis		
RNA	was	 extracted	 following	 the	 Trizol	 protocol	 and	 ribosome	 profiling	 libraries	
were	 generated	 as	 described	 in	 Chapter	 2.	 Read	 filtering	 and	 mapping	 was	
described	 in	 Chapter	 2.	 DESeq2	 was	 used	 to	 calculate	 differential	 expression	
analysis.	Because	there	were	no	differences	in	the	FMRP-IP	between	wild-type	and	
Fmr1-/y	 samples,	 these	 libraries	 were	 combined	 as	 FMRP-IP	 samples.	 FMRP-IP	
libraries	 were	 compared	 to	 RPL4-IP	 libraries,	 and	 both	 FMRP-IP	 and	 RPL4-IP	
mRNAs	 had	 to	 be	 enriched	 4-fold	 over	 IgG	 negative	 control	 to	 be	 considered	
enriched.	 Transcript	 plots	 were	 generated	 using	 reads	 normalized	 by	 counts	 per	
million.	Examples	of	transcript	plots	were	for	the	most	abundant	isoform.	Publically	
available	datasets	used	in	this	chapter	are	from	the	following	publications:	(Darnell,	
Van	Driesche	et	al.	2011,	Ascano,	Mukherjee	et	al.	2012)		
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Table III-2: List of 125 mRNAs enriched in anti-FMRP ribosomes 
Symbol	 Gene	Name	 baseMean	 log2FC	 padj	
1810055G
02Rik	 RIKEN	cDNA	1810055G02	gene	 576.19	 1.68	2.79E-56	
Aff2	 AF4/FMR2	family,	member	2	 1034.63	 0.81	2.57E-12	
Aff4	 AF4/FMR2	family,	member	4	 4494.59	 0.76	9.36E-11	
Aggf1	
angiogenic	 factor	 with	 G	 patch	 and	 FHA	
domains	1	 463.50	 1.05	4.37E-16	
Ankle2	 ankyrin	repeat	and	LEM	domain	containing	2	 1399.93	 0.91	3.61E-22	
Ankrd12	 ankyrin	repeat	domain	12	 2461.85	 1.33	2.06E-15	
Ankrd26	 ankyrin	repeat	domain	26	 476.64	 0.86	3.06E-07	
Apba2	
amyloid	 beta	 (A4)	 precursor	 protein-binding,	
family	A,	member	2	 11535.38	 1.73	1.56E-51	
Apc	 adenomatosis	polyposis	coli	 5861.91	 0.98	4.99E-14	
Arhgap24	 Rho	GTPase	activating	protein	24	 123.39	 0.96	8.85E-08	
Asxl3	 additional	sex	combs	like	3	(Drosophila)	 224.74	 1.16	2.11E-13	
Atxn1l	 ataxin	1-like	 804.53	 2.51	2.95E-97	
Bahcc1	 BAH	domain	and	coiled-coil	containing	1	 302.33	 1.23	4.23E-16	
Bzrap1	 benzodiazepine	receptor	associated	protein	1	 730.54	 0.82	9.16E-14	
Cacna1a	 calcium	channel,	voltage-dependent,	P/Q	type,	 3652.75	 0.86	1.60E-10	
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alpha	1A	subunit	
Cage1	 cancer	antigen	1	 90.41	 1.09	7.55E-08	
Cbfa2t3	
core-binding	factor,	runt	domain,	alpha	subunit	
2,	translocated	to,	3	(human)	 312.90	 0.77	2.53E-08	
Ccdc61	 coiled-coil	domain	containing	61	 165.67	 1.04	3.08E-11	
Cep162	 centrosomal	protein	162	 225.17	 0.76	1.69E-05	
Cep170b	 centrosomal	protein	170B	 4892.02	 0.78	4.42E-12	
Cep85l	 centrosomal	protein	85-like	 407.50	 0.80	2.61E-08	
Chgb	 chromogranin	B	 12245.34	 0.90	1.10E-06	
Cic	 capicua	transcriptional	repressor	 3099.18	 0.96	3.67E-13	
Cobl	 cordon-bleu	WH2	repeat	 8003.88	 2.15	1.73E-75	
Cpeb4	
cytoplasmic	 polyadenylation	 element	 binding	
protein	4	 2578.38	 1.00	3.31E-26	
Csrp2bp	
cysteine	 and	 glycine-rich	 protein	 2	 binding	
protein	 457.58	 1.33	5.52E-30	
Dbn1	 drebrin	1	 2881.80	 1.51	7.64E-18	
Diap2	 NA	 1086.83	 0.89	1.56E-18	
Dis3l	 DIS3	like	exosome	3'-5'	exoribonuclease	 754.57	 1.37	2.51E-24	
Dlg5	 discs,	large	homolog	5	(Drosophila)	 302.32	 0.77	1.94E-06	
Dnajc21	 DnaJ	 heat	 shock	 protein	 family	 (Hsp40)	 241.09	 0.94	3.39E-09	
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member	C21	
Donson	 downstream	neighbor	of	SON	 265.40	 0.99	2.15E-10	
Dzip1	 DAZ	interacting	protein	1	 106.78	 0.77	4.82E-05	
E130308A
19Rik	 RIKEN	cDNA	E130308A19	gene	 368.56	 1.90	1.55E-36	
Ears2	 glutamyl-tRNA	synthetase	2,	mitochondrial	 378.14	 1.77	2.03E-32	
Ep300	 E1A	binding	protein	p300	 2366.79	 1.12	2.91E-31	
Etv1	 ets	variant	1	 2921.93	 1.00	1.30E-23	
Fam178a	 family	with	sequence	similarity	178,	member	A	 372.39	 0.97	6.69E-11	
Fbxo34	 F-box	protein	34	 1181.79	 0.90	5.76E-07	
Foxp1	 forkhead	box	P1	 3828.83	 1.23	1.59E-32	
Fxr2	
fragile	 X	 mental	 retardation,	 autosomal	
homolog	2	 2993.93	 1.56	1.52E-21	
Gigyf1	 GRB10	interacting	GYF	protein	1	 2695.72	 1.32	2.84E-09	
Gigyf2	 GRB10	interacting	GYF	protein	2	 2732.45	 1.76	3.24E-51	
Gpsm1	
G-protein	 signalling	modulator	 1	 (AGS3-like,	 C.	
elegans)	 2707.45	 1.77	1.58E-31	
Gsn	 gelsolin	 6627.25	 0.79	8.28E-07	
Heatr3	 HEAT	repeat	containing	3	 1384.23	 1.04	3.79E-24	
Hgf	 hepatocyte	growth	factor	 563.28	 1.53	7.26E-16	
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Ift172	 intraflagellar	transport	172	 1430.96	 0.77	1.79E-14	
Il16	 interleukin	16	 114.38	 0.98	7.11E-08	
Irf9	 interferon	regulatory	factor	9	 121.98	 1.02	4.29E-09	
Jade3	 jade	family	PHD	finger	3	 262.10	 1.69	1.64E-35	
Kdm4a	 lysine	(K)-specific	demethylase	4A	 2304.25	 1.27	1.88E-37	
Kdm5c	 lysine	(K)-specific	demethylase	5C	 1700.45	 0.99	1.66E-24	
Kif1b	 kinesin	family	member	1B	 18793.61	 0.75	2.97E-19	
Kif21b	 kinesin	family	member	21B	 1076.81	 0.77	5.11E-12	
Klf15	 Kruppel-like	factor	15	 694.06	 1.15	4.28E-21	
Leo1	
Leo1,	 Paf1/RNA	 polymerase	 II	 complex	
component	 1251.26	 1.01	4.14E-17	
Lrrc7	 leucine	rich	repeat	containing	7	 3586.39	 0.97	2.15E-36	
Map4k3	
mitogen-activated	protein	kinase	kinase	kinase	
kinase	3	 1661.95	 1.02	2.52E-21	
Mapk8ip3	
mitogen-activated	 protein	 kinase	 8	 interacting	
protein	3	 8072.36	 0.91	4.80E-16	
Mark2	 MAP/microtubule	affinity	regulating	kinase	2	 3073.59	 1.02	1.21E-20	
Mast4	
microtubule	associated	serine/threonine	kinase	
family	member	4	 1547.78	 1.50	1.76E-41	
Mepce	 methylphosphate	capping	enzyme	 878.18	 0.81	1.57E-13	
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Mgat5	 mannoside	acetylglucosaminyltransferase	5	 2005.33	 0.79	1.41E-17	
Myh10	 myosin,	heavy	polypeptide	10,	non-muscle	 9154.52	 1.00	4.14E-09	
Myh14	 myosin,	heavy	polypeptide	14	 481.89	 0.82	3.21E-08	
Myh9	 myosin,	heavy	polypeptide	9,	non-muscle	 2311.50	 1.10	2.44E-12	
Myo5a	 myosin	VA	 13206.64	 0.82	6.62E-07	
Myo9b	 myosin	IXb	 306.78	 0.78	2.69E-06	
Ncoa2	 nuclear	receptor	coactivator	2	 3784.40	 1.62	2.36E-77	
Ncor1	 nuclear	receptor	co-repressor	1	 3223.13	 1.08	2.41E-13	
Nefh	 neurofilament,	heavy	polypeptide	 3356.17	 1.88	2.22E-39	
Nipbl	 Nipped-B	homolog	(Drosophila)	 1735.90	 1.59	1.97E-59	
Notch1	 notch	1	 957.30	 1.02	1.16E-08	
Optn	 optineurin	 919.50	 1.76	1.83E-45	
Pard3	 par-3	family	cell	polarity	regulator	 462.95	 1.38	7.05E-26	
Pcf11	
PCF11	 cleavage	 and	 polyadenylation	 factor	
subunit	 764.77	 0.79	2.58E-08	
Pcm1	 pericentriolar	material	1	 4243.03	 0.78	1.69E-12	
Phactr2	 phosphatase	and	actin	regulator	2	 424.24	 1.76	1.45E-34	
Polrmt	
polymerase	 (RNA)	 mitochondrial	 (DNA	
directed)	 1489.95	 2.40	
1.30E-
102	
Ppargc1a	 peroxisome	 proliferative	 activated	 receptor,	 1348.91	 1.61	2.19E-48	
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gamma,	coactivator	1	alpha	
Ppip5k2	 diphosphoinositol	pentakisphosphate	kinase	2	 476.55	 1.70	9.13E-47	
Ppp1r9a	
protein	 phosphatase	 1,	 regulatory	 (inhibitor)	
subunit	9A	 1128.85	 1.06	5.72E-14	
Prkdc	
protein	 kinase,	 DNA	 activated,	 catalytic	
polypeptide	 1968.06	 1.44	1.57E-15	
Ptpn2	
protein	 tyrosine	 phosphatase,	 non-receptor	
type	2	 577.18	 1.18	3.43E-15	
Rasgrp2	 RAS,	guanyl	releasing	protein	2	 5395.77	 1.76	1.14E-16	
Rbfox2	
RNA	 binding	 protein,	 fox-1	 homolog	 (C.	
elegans)	2	 6220.95	 1.68	1.17E-66	
Rbm12b1	 RNA	binding	motif	protein	12	B1	 91.55	 1.07	4.38E-08	
Rbm12b2	 RNA	binding	motif	protein	12	B2	 158.43	 0.83	4.43E-06	
Rexo1	 REX1,	RNA	exonuclease	1	 658.14	 1.02	2.00E-08	
Rgag4	 retrotransposon	gag	domain	containing	4	 632.29	 1.11	1.35E-25	
Rnf115	 ring	finger	protein	115	 1989.70	 0.82	3.76E-16	
Rnf185	 ring	finger	protein	185	 824.41	 0.96	9.67E-21	
Runx1t1	
runt-related	transcription	factor	1;	translocated	
to,	1	(cyclin	D-related)	 904.65	 1.00	2.58E-20	
Sap130	 Sin3A	associated	protein	 4473.83	 2.33	5.99E-50	
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Setd4	 SET	domain	containing	4	 95.62	 0.96	4.98E-05	
Sgpp1	 sphingosine-1-phosphate	phosphatase	1	 765.28	 0.94	9.63E-18	
Sipa1l2	 signal-induced	proliferation-associated	1	like	2	 933.91	 0.75	2.87E-14	
Sptbn1	 spectrin	beta,	non-erythrocytic	1	 4553.37	 0.86	2.14E-06	
Srcin1	 SRC	kinase	signaling	inhibitor	1	 9607.66	 1.30	3.36E-30	
Tbc1d14	 TBC1	domain	family,	member	14	 925.71	 1.00	6.65E-25	
Tet2	 tet	methylcytosine	dioxygenase	2	 189.27	 0.80	1.50E-06	
Thbs1	 thrombospondin	1	 154.52	 0.98	2.62E-07	
Thbs2	 thrombospondin	2	 390.19	 1.11	8.54E-09	
Thrap3	 thyroid	hormone	receptor	associated	protein	3	 5146.33	 0.75	
0.00223
9933	
Tjap1	 tight	junction	associated	protein	1	 142.86	 1.11	7.62E-11	
Tnip1	 TNFAIP3	interacting	protein	1	 1392.44	 2.09	6.55E-76	
Tnrc18	 trinucleotide	repeat	containing	18	 1613.71	 1.17	6.46E-19	
Tnrc6b	 trinucleotide	repeat	containing	6b	 2374.83	 1.20	2.59E-11	
Triobp	 TRIO	and	F-actin	binding	protein	 222.01	 0.94	2.40E-05	
Trp53bp2	
transformation	 related	 protein	 53	 binding	
protein	2	 884.02	 0.83	1.47E-09	
Ubap2l	 ubiquitin-associated	protein	2-like	 4544.19	 1.02	2.12E-10	
Zbtb38	 zinc	finger	and	BTB	domain	containing	38	 1932.08	 1.27	9.44E-45	
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Zdbf2	 zinc	finger,	DBF-type	containing	2	 536.07	 0.98	5.82E-10	
Zfp106	 zinc	finger	protein	106	 1662.22	 1.31	7.99E-43	
Zfp14	 zinc	finger	protein	14	 141.03	 0.79	3.54E-06	
Zfp191	 NA	 1088.38	 0.79	4.11E-12	
Zfp40	 zinc	finger	protein	40	 263.96	 0.75	7.01E-07	
Zfp407	 zinc	finger	protein	407	 626.89	 0.80	3.33E-08	
Zfp52	 zinc	finger	protein	52	 81.59	 1.09	1.02E-07	
Zfp800	 zinc	finger	protein	800	 535.66	 0.80	4.43E-12	
Zfyve9	 zinc	finger,	FYVE	domain	containing	9	 1257.06	 0.76	2.50E-12	
Zkscan3	 zinc	finger	with	KRAB	and	SCAN	domains	3	 425.58	 0.97	2.09E-10	
Znfx1	 zinc	finger,	NFX1-type	containing	1	 5528.45	 2.80	
1.63E-
185	
Zscan12	 zinc	finger	and	SCAN	domain	containing	12	 806.98	 3.11	2.12E-93	
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CHAPTER IV DISCUSSION AND CONCLUSIONS 
Summary 
mGluR5 signaling is required for a form of synaptic plasticity (mGluR-LTD) that 
is dysregulated in multiple mouse models of autism, including TSC and FXS. Previous 
work found that Tsc2+/- mice, which model TSC autism, have decreased protein synthesis 
in the hippocampus and deficient LTD. Because restoring protein synthesis corrects the 
decreased LTD in Tsc2+/- mice, identifying the mRNAs dysregulated in these animals 
may provide insight into their impaired synaptic function. In addition, the mRNAs 
responsive to mGluR5 signaling are largely unknown, and their identities are important 
because they may underlie the altered mGluR-LTD in multiple mouse models of autism. 
Our project sought to identify mRNAs responsive to mGluR5 signaling in the normal and 
Tsc2+/- hippocampus by using unbiased, high resolution approaches: RNA-seq and 
ribosome profiling. We find that targets of the RNA-binding protein FMRP have 
increased RNA abundance in Tsc2+/- mice as well as following mGluR5 signaling. 
Conversely, in Fmr1-/y mice, a previous study finds that FMRP binding targets have 
decreased mRNA levels (Shah, Molinaro et al. 2020). mGluR-LTD activates 
eEF2K/eEF2 signaling to converge on slowing ribosome movement, and we find that 
Tsc2+/- mice have impaired mGluR5-eEF2K signaling. Pharmacologically slowing 
ribosomes with cycloheximide rescues deficient mGluR-LTD in Tsc2+/- mice, suggesting 
a novel link between ribosome translocation and synaptic plasticity deficits in these 
animals.  
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FMRP binding targets connects mGluR-LTD with two mouse models of 
autism  
A goal of our project was to identify the mRNAs dysregulated in TSC autism 
mice and to determine if these mRNAs overlap with other mouse models of autism. Our 
results suggest that FMRP binding targets are altered bidirectionally in Tsc2+/- and Fmr1-
/y mice and regulated by mGluR-LTD. The group of FMRP binding targets may explain 
the findings from a previous study, where a combined Tsc2+/- and Fmr1-/y mouse model 
can rescue protein synthesis, mGluR-LTD and behavior to wild-type levels (Auerbach, 
Osterweil et al. 2011). To assess whether this group of mRNAs are responsible for the 
phenotypes of the TSC and FXS mice, one should determine whether FMRP binding 
targets return to wild-type levels in a combined Tsc2+/-and Fmr1-/y mouse. Interestingly, 
there is a correlation between FMRP binding stringency and the degree of change in 
Tsc2+/- animals and following mGluR-LTD, where mRNAs bound by more FMRP 
increase in abundance more than mRNAs bound with less FMRP. This would suggest 
that TSC2 regulates FMRP activity, perhaps through altered signaling. We do not observe 
changes in mRNA, RPF, or protein levels of FMRP in Tsc2+/- mice, suggesting that the 
increased abundance of FMRP binding targets could arise from changes in FMRP 
activity, for example through phosphorylation. Following mGluR5 signaling, 
dephosphorylation of FMRP promotes its release from miRNA-RISC complexes and 
relieves translational repression on its target PSD-95 mRNA, a synaptic scaffold 
(Nalavadi, Muddashetty et al. 2012). Phosphorylation of FMRP can also enhances phase 
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separation with RNA into granules to promote deadenylation and translational repression 
(Kim, Tsang et al. 2019, Tsang, Arsenault et al. 2019).  
TSC2: potential regulator of mGluR-LTD signaling to eEF2 and FMRP 
TSC2 is an inhibitor of mTORC1 signaling, so our initial hypothesis was that 
increased mTORC1 signaling to 4E-BP1 and S6K1 dependent translation would mediate 
the changes in Tsc2+/- animals. However, we do not find clear evidence of such 
translational dysregulation (i.e., no enrichment of TOP motifs or long, structured 5′UTR 
in differentially expressed mRNAs). Although we observe a trend for increased phospho-
rpS6 in Tsc2+/- mice, a common readout for mTORC1-S6K1 activation, the role of 
phospho-rpS6 on translation is unclear. Instead, our work finds that signaling to 
eEF2K/eEF2 phosphorylation, a signaling pathway required for mGluR-LTD, is basally 
elevated in Tsc2+/- mice and no longer responsive to mGluR5 signaling. Although eEF2K 
is a substrate of mTORC1-S6K1 signaling, the elevated levels of phospho-eEF2 is 
opposite of the direction predicted by mTORC1 activation. This suggests that the 
dysregulated eEF2K/eEF2 signaling in Tsc2+/- mice may be from an mTORC1-
independent process. Increased levels of phospho-eEF2 inhibit general translation, and 
our results are consistent with a previous finding that Tsc2+/- mice have decreased protein 
synthesis instead of the predicted elevated translation from mTORC1 hyperactivation 
(Auerbach, Osterweil et al. 2011).  
The altered eEF2K/eEF2 signaling in Tsc2+/ animals may link the changes in 
FMRP binding targets and impaired synaptic plasticity in these mice. mGluR5-eEF2K 
and mGluR5-FMRP signaling regulates synthesis of specific proteins required for 
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mGluR-LTD, but previous work suggest that these pathways are parallel and distinct 
(Park, Park et al. 2008). Because we observe elevated levels of FMRP binding targets 
that correlates with increased eEF2 phosphorylation, our results suggest that TSC2 may 
be upstream of mGluR5-eEF2K and mGluR5-FMRP signaling. Thus, TSC2 may link 
these two important signaling pathways required for mGluR-LTD.  
Altered eEF2K/eEF2 signaling may underlie other phenotypes in Tsc2+/- mice 
Our results demonstrate a novel link between dysregulated eEF2K/eEF2 signaling 
and a mouse model of TSC autism, where phospho-eEF2 levels are basally elevated and 
no longer responsive to mGluR5 activation. A future direction of inquiry would be to 
determine if targeting eEF2K/eEF2 signaling could ameliorate other phenotypes of the 
Tsc2+/- mice. For example, eEF2K/eEF2 is required for multiple forms of protein 
synthesis-dependent synaptic plasticity, learning and memory, and maintaining the 
excitatory/inhibitory balance in the brain, all of which show evidence of disruptions in 
Tsc2+/- animals (Sutton, Taylor et al. 2007, Park, Park et al. 2008, Gildish, Manor et al. 
2012, McCamphill, Farah et al. 2015, Weng, Chen et al. 2016, Heise, Taha et al. 2017, 
Antoine, Langberg et al. 2019). Our data suggest that slowing ribosome movement with 
cycloheximide to mimic phospho-eEF2 can rescue mGluR-LTD in Tsc2+/- mice. 
However, a limitation to this interpretation is that cycloheximide has effects independent 
of inhibiting ribosome movement, such as internalization of surface epidermal growth 
factor receptors and inhibiting actin cytoskeletal rearrangement (Oksvold, Pedersen et al. 
2012, Chang, Tsai et al. 2013, Darvishi and Woldemichael 2016). Additional experiments 
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to target eEF2K specifically would further support if restoring eEF2K/eEF2 signaling 
rescues mGluR-LTD, behavior, and protein synthesis in Tsc2+/- mice.  
Crosstalk of eEF2K/eEF2 signaling and TOP mRNAs in Tsc2+/- animals 
The TOP mRNAs are a distinct group that contain an oligopyrimidine tract in the 
5′UTR, encode many components of the translation machinery, and are sensitive to 
mTORC1 regulation (Thoreen, Chantranupong et al. 2012). In Tsc2+/- animals, we find 
that the TOP mRNAs have decreased mRNA and mildly increased RPFs levels. Although 
the slight increase in translation of TOP mRNAs would be consistent with increased 
mTORC1 signaling, the decrease in RNA abundance is more dramatic and overall, likely 
leads to decreased levels of ribosomal proteins. Thus, it is unclear if initial mTORC1 
hyperactivation drives excessive TOP mRNA translation in Tsc2+/- animals, which then 
compensates by decreasing RNA levels. Regardless, we observe evidence of dysregulated 
eEF2K/eEF2 signaling and the TOP mRNAs in Tsc2+/- animals, which may be mediated 
through the RBP LARP1. LARP1 directly binds TOP mRNAs to bidirectionally function 
as an activator or repressor of mRNA stability and translation based on phosphorylation 
status (Gentilella, Moron-Duran et al. 2017). There is evidence of cross talk between 
eEF2 phosphorylation, LARP1, and regulation of TOP mRNAs, where deficiency in 
ribosomal proteins activates a ribosomal stress response that increases eEF2 
phosphorylation (Gismondi, Caldarola et al. 2014). LARP1 deficiency can also decrease 
ribosome levels, activate a ribosomal stress response, and increase eEF2K/eEF2 signaling 
(Gentilella, Moron-Duran et al. 2017). The role of LARP1 is unexplored in the brain, and 
a future direction of inquiry would be to determine if LARP1 activity is altered in Tsc2+/- 
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mice and mediates the decrease in TOP mRNA levels. Of note, we do not have evidence 
of altered mRNA or RPF levels of Larp1 in Tsc2+/- animals. An unbiased approach such 
as phosphoproteomics could identify changes in LARP1 phosphorylation and other 
components of TSC-Rheb signaling in the Tsc2+/- mice. 
Role of mRNA turnover and stability in mGluR-LTD 
mGluR-LTD is a protein-synthesis dependent form of synaptic plasticity that is 
dysregulated in multiple mouse models of autism and shows promise in ameliorating 
ASD-like behaviors (Bear, Huber et al. 2004, Kelly, Schaeffer et al. 2018). However, the 
identities of the mGluR5-responsive mRNAs in the intact hippocampus are largely 
unknown. Using unbiased RNA-seq and ribosome profiling, our study identified these 
mGluR5-responsive mRNAs. At 5 minutes after induction of mGluR5 signaling, we 
observe a rapid increase in mRNAs that are enriched for synaptic function and FMRP 
binding targets. The current model in the field is that FMRP acts as a translational 
repressor of mRNAs required for mGluR-LTD. Our findings are consistent with a model 
of FMRP as a regulator of mGluR5-responsive mRNAs, but also suggests a role of 
FMRP in regulating mRNA turnover. Under basal conditions, FMRP may promote 
degradation of specific mRNAs. Upon mGluR5 activation, other labs have shown that 
FMRP is inactivated by post-translational modifications and degradation, which may 
allow for increased stabilization of mRNA levels (Nalavadi, Muddashetty et al. 2012, 
Huang, Ikeuchi et al. 2015).  
Traditionally, translational control of mGluR-LTD has been the main focus of 
research, and our observation of rapidly increased and decreased mRNAs following 
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mGluR5 signaling was surprising, because we expected a stronger translational response. 
Because the transcriptional inhibitor actinomycin D does not block mGluR-LTD (arguing 
that RNA synthesis is not required) and because we did not observe induction of 
immediate early genes (Arc, c-fos, Egr-1), we speculate that the rapid changes in mRNA 
abundance is from altered mRNA turnover. An RNA metabolic labeling assay is required 
to demonstrate altered mRNA turnover following mGluR-LTD in hippocampal slices, 
although this is technically challenging to perform in tissue.  
Our study suggests that regulators of mRNA turnover are likely to be important 
for mGluR5 signaling. One such example could be miRNAs. Synaptic stimulation can 
promote rapid degradation of miRNAs or dissociation of miRNAs from mRNA targets to 
prevent mRNA degradation and relieve translational repression. In retinal neurons, 
multiple miRNAs are quickly degraded following a light stimulus (Krol, Busskamp et al. 
2010). It is unknown if rapid degradation of specific miRNAs occurs after mGluR5 
signaling and if so, whether these miRNAs are required for mGluR-LTD. miRNA 
association with targets can also be rapidly controlled by synaptic activity. 
Phosphorylated FMRP interacts with miR-125a-RISC to repress translation of the 
synaptic scaffold PSD-95 mRNA (Edbauer, Neilson et al. 2010, Muddashetty, Nalavadi 
et al. 2011). Upon mGluR5 signaling, FMRP is dephosphorylated and releases miR-125a-
RISC from PSD-95 mRNA (Muddashetty, Nalavadi et al. 2011). Because FMRP targets 
increase in abundance following mGluR5 signaling in our data, an unanswered question 
is whether miR-125a or other miRNAs are required for stabilization of these mRNAs 
following mGluR-LTD. 
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Another mechanism of rapid mRNA turnover is through control of the poly(A) 
tail. Shortening of the poly(A) tail often leads to destabilization of the mRNA by 
recruitment of decay factors. Lengthening of the poly(A) tail promotes circularization of 
the mRNA for initiation by facilitating the interaction of polyA Binding Protein (PABP) 
with eukaryotic initiation factor 4E (eIF4E), the cap-binding protein. Thus, lengthening 
of the poly(A) tail length can allow for both rapid stabilization and translation of 
mRNAs, and the importance of this process has been demonstrated for other forms of 
synaptic plasticity. The deadenylase CNOT7 is quickly degraded following chemical 
LTP in cultured neurons, and this correlates with an increase of dendritic poly(A) signal 
within 30 seconds, which is likely from rapid mRNA stabilization and increases in 
poly(A) tail length (McFleder, Mansur et al. 2017). Thus, mGluR5 signaling may 
promote poly(A) tail lengthening by inactivating deadenylases, activating poly(A) 
polymerases, and/or dissociation of miRNAs to increase stability and translation of target 
mRNAs. One method to support if mRNAs are stabilized following mGluR5 activation is 
to measure poly(A) tail length of specific mRNAs by an unbiased method such as TAIL-
Seq (Chang, Lim et al. 2014). This approach is technically easier to perform than 
metabolic labeling of hippocampal slices to measure mRNA turnover. To determine 
whether mRNA stabilization is required for mGluR5 signaling, ideally one would acutely 
inhibit mRNA turnover. However, this approach is challenging because of the lack of 
chemical inhibitors that specifically block mRNA degradation. Remaining questions 
include if specific deadenylases and poly(A) polymerases are regulated by mGluR5 
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signaling and if so, do they interact with FMRP to control abundance of mRNAs required 
for mGluR-LTD.  
Limitations of mouse models of TSC and whole tissue sequencing 
A limitation of our study is identifying changes within a heterogeneous tissue 
such as the brain, particularly for Tsc2+/- mice where the disturbances are mild. We chose 
a germline heterozygote model to reflect that one allele is mutated in humans with TSC. 
The Tsc2+/- mice have phenotypes that recapitulate ASD-like behavior in humans, such as 
impaired social interactions, learning, and synaptic plasticity. However, these mice (along 
with the Tsc1+/- mouse model) do not develop spontaneous benign tumor growth or 
seizures characteristic of the disorder TSC (von der Brelie, Waltereit et al. 2006, 
Ehninger, Han et al. 2008, Auerbach, Osterweil et al. 2011, Potter, Basu et al. 2013, 
Antoine, Langberg et al. 2019, Basu, Riordan et al. 2019). This highlights some of the 
challenges in using mice to model the highly variable disorder TSC and is suggestive of 
complex genetic and environmental interactions that factor into disease manifestation in 
humans. Alternative TSC mouse models include neuron-specific Tsc2 deletion and a 
hypomorph mouse where TSC2 levels are roughly 7% of wild-type mice (Yuan, Tsai et 
al. 2012). These mouse models have impaired social interaction and epilepsy 
characteristic of TSC, but it is unknown if they have an mGluR-LTD phenotype, which 
was a major focus of our work. Because work from patients and mouse models of TSC 
support a gene-dosage effect from loss of TSC1 and TSC2, such extreme mouse models 
may lead to conclusions not reflective of the underlying molecular dysfunction in TSC.  
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Another limitation is that TSC/mTOR signaling has cell-type specific effects that 
are missed by our whole tissue experimental approach. Methods to identify cell-type 
specific mRNA expression are RiboTag and Translating Ribosome Affinity Purification 
(TRAP) (Sanz, Yang et al. 2009, Heiman, Kulicke et al. 2014). When combined with a 
cell-type specific Cre recombinase mouse, both methods allow for epitope tagging of a 
core ribosomal protein. mRNA-ribosome complexes from specific cells can be enriched 
by immunoprecipitation. RiboTag and TRAP could be used to identify changes in 
excitatory neurons from Tsc2+/- mice, but these methods lack the cell-type specific total 
mRNA comparison and thus, cannot distinguish if mRNA levels or translation drive 
differences in mRNA-ribosome association.  
A goal of this study was to identify mRNAs that are dysregulated in Tsc2+/- mice 
following mGluR5 signaling, which was challenging given the mild changes and 
heterogeneity of the hippocampus. Because mGluR-LTD depends on protein synthesis in 
the neuropil (an area enriched for dendrites of CA1 pyramidal neurons) of the 
hippocampus, one approach is to micro-dissect the neuropil from the cell body of 
neurons. This approach was used by other laboratories to identify specific features in 
dendrites relative to the soma and has elucidated many unique aspects of dendritic 
neurobiology, such as enrichment of select mRNAs populations, alternative 3′UTR 
usage, and differential ribosome usage (Cajigas, Tushev et al. 2012, Tushev, Glock et al. 
2018, Biever, Glock et al. 2020). Of note, micro-dissecting the neuropil from the soma 
requires a heroic effort to obtain sufficient material for RNA-seq and ribosome profiling. 
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As a perspective, our collective ribosome profiling and RNA-seq experiments utilized 
hippocampal slices with the cell body and dendrites from over 100 mice. 
Concluding remarks  
We initiated this study to identify the 1) mRNAs dysregulated in a mouse model 
of TSC autism and 2) responsive to induction of mGluR-LTD. Using RNA-seq and 
ribosome profiling, our work reveals that targets of FMRP are a common group of 
mRNAs that are elevated in TSC mice and rapidly increased following mGluR-LTD 
signaling. In addition, TSC mice have dysregulated eEF2K/eEF2 signaling to ribosome 
movement. Collectively, this work suggests a link between mGluR5-dependent 
eEF2K/eEF2 signaling, FMRP binding targets, and synaptic plasticity impairment in a 
mouse model of TSC autism. Future work is needed to determine if manipulating 
eEF2K/eEF2 signaling can rescue levels of FMRP binding targets and correct ASD-like 
behaviors in TSC mice.  
Rapid protein synthesis is required for mGluR-LTD. We identified hundreds of 
mRNAs that rapidly increase and decrease in abundance following mGluR5 signaling. 
Our work suggests that rapid remodeling of the synaptic proteome required for mGluR-
LTD likely includes mRNA turnover. Future work includes identifying possible 
regulators of mRNA degradation during mGluR-LTD, which may reveal novel 
mechanisms relevant to synaptic plasticity, higher cognitive function, and ASD-like 
behaviors.  
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